415 results on '"Hyun Moo Lee"'
Search Results
102. Role of Magnetic Resonance Imaging Using Prostate Imaging-Reporting and Data System Version 2 to Predict Clinically Significant Cancer After Radical Prostatectomy in Very Low-Risk or Low-Risk Prostate Cancer
- Author
-
Byong Chang Jeong, Chan Kyo Kim, Seong Soo Jeon, Jae Ho Yoo, Seong Il Seo, Tae Heon Kim, Wan Song, Hyun Moo Lee, Byung Kwan Park, Han Yong Choi, and Hwang Gyun Jeon
- Subjects
Oncology ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Prostatectomy ,medicine.medical_treatment ,Urology ,Cancer ,Magnetic resonance imaging ,medicine.disease ,Prostate cancer ,medicine.anatomical_structure ,Prostate ,Internal medicine ,Medicine ,Very low risk ,Prostate neoplasm ,business - Published
- 2017
- Full Text
- View/download PDF
103. Incidence of Pathological Downgrading and Treatment Outcome After Radical Prostatectomy in Patients With Biopsy Confirmed High Gleason Score Prostate Cancer
- Author
-
Hyun Moo Lee, Seong Soo Jeon, Byong Chang Jeong, Jun Phil Na, Hwang Gyun Jeon, Han Yong Choi, Min Yong Kang, Hyun Hwan Sung, Tae Heon Kim, Seong Il Seo, and Jae Ho Yoo
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Prostatectomy ,Incidence (epidemiology) ,medicine.medical_treatment ,Treatment outcome ,Urology ,medicine.disease ,Prostate cancer ,Biopsy ,medicine ,In patient ,business ,Pathological - Published
- 2017
- Full Text
- View/download PDF
104. Comparison of Oncologic Outcomes and Complications According to Surgical Approach to Radical Prostatectomy: Special Focus on the Perineal Approach
- Author
-
Seong Soo Jeon, Seong Il Seo, Wan Song, Hwang Gyun Jeon, Joon Hyung Park, Hyun Moo Lee, Byong Chang Jeong, and Han Yong Choi
- Subjects
Male ,Biochemical recurrence ,medicine.medical_specialty ,Laparoscopic radical prostatectomy ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Perineum ,Disease-Free Survival ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,Robotic Surgical Procedures ,medicine ,Humans ,Laparoscopy ,Aged ,Retrospective Studies ,Prostatectomy ,medicine.diagnostic_test ,Wound dehiscence ,business.industry ,Prostatic Neoplasms ,Middle Aged ,medicine.disease ,Survival Analysis ,Treatment Outcome ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,business ,Radical perineal prostatectomy ,Radical retropubic prostatectomy - Abstract
The objective of the study was to compare oncologic outcomes and complications in patients with prostate cancer who underwent radical perineal prostatectomy (RPP), radical retropubic prostatectomy (RRP), laparoscopic radical prostatectomy (LRP), or robotic-assisted radical prostatectomy (RARP).We retrospectively reviewed 2617 patients who underwent RPP (n = 673), RRP (n = 396), LRP (n = 223), or RARP (n = 1325) between 1995 and 2013. Clinicopathological outcomes were compared according to surgical approach. Kaplan-Meier and Cox regression analyses were carried out to assess oncologic outcomes. Complications were stratified according to the Clavien classification system.The 5-year biochemical recurrence (BCR)-free survival after RPP was 75.3%, which was higher than for RRP (71.4%; P = .007) and comparable with LRP (76.1%; P = .666) and RARP (75.3%; P = .898). In multivariate analysis, RPP was comparable with LRP (P = .591) and RARP (P = .089) whereas RRP was associated with increased BCR (P .001). No significant difference was seen in 5-year cancer-specific survival (RPP, 99.0%; RRP, 98.7%; LRP, 100.0%; and RARP, 99.8%; P = .071). The 5-year overall survival after RPP was 97.0%, which was lower than for RARP (99.6%; P = .007), but comparable with RRP (96.2%; P = .792) and LRP (99.1%; P = .606). Overall complication rates were 25.1% for RPP, 36.4% for RRP, 16.1% for LRP, and 9.4% for RARP (P .001), respectively. After RPP, wound dehiscence (10.3%) was the most common complication. However, approximately 75% of complications were minor.RPP showed acceptable oncologic outcomes compared with other surgical approaches. Careful attention is required to prevent wound dehiscence.
- Published
- 2017
- Full Text
- View/download PDF
105. Pathological and oncological features of Korean prostate cancer patients eligible for active surveillance: analysis from the K-CaP registry
- Author
-
Kwang Suk Lee, Ji Youl Lee, Kyo Chul Koo, Seok-Soo Byun, Jun Hyuk Hong, In Young Choi, Seung Hwan Lee, Koon Ho Rha, Choung Soo Kim, Jae Yong Jeong, Hyun Moo Lee, Byung Ha Chung, and Sung Kyu Hong
- Subjects
Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,030232 urology & nephrology ,urologic and male genital diseases ,Preoperative care ,Androgen deprivation therapy ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Interquartile range ,Internal medicine ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Registries ,P-Chloroamphetamine ,Aged ,Prostatectomy ,business.industry ,Prostatic Neoplasms ,General Medicine ,Middle Aged ,Prostate-Specific Antigen ,medicine.disease ,Prostate-specific antigen ,030220 oncology & carcinogenesis ,business ,Watchful waiting - Abstract
A web-based multicenter Korean Prostate Cancer Database (K-CaP) was established to provide urologists with information on Korean prostate cancer (PCa) patients treated with radical prostatectomy (RP). We utilized the K-CaP registry to identify pathological features and oncological outcomes of Korean PCa patients eligible for active surveillance (AS).The K-CaP registry consisted of 6415 patients who underwent RP from May 2001 to April 2013 at five institutions. Preoperative clinicopathological data were collected to identify patients who were eligible for at least one contemporary AS protocol. Patients who had received neoadjuvant androgen deprivation therapy or a 5α-reductase inhibitor, who had10 total biopsy cores, or who had incomplete data were excluded. Biochemical recurrence (BCR) was defined as prostate-specific antigen (PSA) level ≥0.2 ng/ml following RP.A total of 560 patients were identified, and the median follow-up period was 52.0 (interquartile range, 39.0-67.3) months. Pathologically insignificant PCa, defined as organ-confined disease with Gleason score ≤6 was observed in 314 (56.1%) patients. Pathological upgrading (Gleason score ≥7) and upstaging (≥pT3) were observed in 237 (42.3%) and 75 (13.4%) patients, respectively. Unfavorable disease (extracapsular extension, seminal vesicle invasion, or Gleason score ≥8) was observed in 85 (15.2%) patients. PSA density ≤0.2 ng/ml/cc and maximal single core involvement ≤20% were revealed as independent preoperative predictors of pathologically insignificant PCa.Contemporary Western AS protocols unreliably predict pathologically insignificant PCa in Korean men. Korean men may harbor more aggressive PCa features than Western men, and thus, a more stringent AS protocol is needed.
- Published
- 2017
- Full Text
- View/download PDF
106. Alcoholic Wernicke Encephalopathy Presenting with Ataxic Gait and Diplopia
- Author
-
Hyun Moo Lee, Ki Dong Ko, Kyoung Kon Kim, Hee Young Hwang, In Cheol Hwang, Kyu Rae Lee, Heuy Sun Suh, and Yoon Taek Lee
- Subjects
Diplopia ,medicine.medical_specialty ,Physical medicine and rehabilitation ,Wernicke Encephalopathy ,business.industry ,Medicine ,Ataxic Gait ,medicine.symptom ,business - Published
- 2017
- Full Text
- View/download PDF
107. Can partial nephrectomy provide equal oncological efficiency and safety compared with radical nephrectomy in patients with renal cell carcinoma (≥4 cm)? A propensity score–matched study
- Author
-
Jong Jin Oh, Chang Wook Jeong, Hakmin Lee, Seong Il Seo, Seok-Soo Byun, Cheol Kwak, Seong Soo Jeon, Han Yong Choi, Hyun Moo Lee, and Byong Chang Jeong
- Subjects
Male ,medicine.medical_specialty ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Nephrectomy ,03 medical and health sciences ,0302 clinical medicine ,Renal cell carcinoma ,medicine ,Humans ,In patient ,Renal cell carcinoma 4 ,Propensity Score ,Carcinoma, Renal Cell ,Neoplasm Staging ,Proportional hazards model ,business.industry ,Standard treatment ,Perioperative ,Middle Aged ,medicine.disease ,Survival Analysis ,Kidney Neoplasms ,Surgery ,Treatment Outcome ,Oncology ,030220 oncology & carcinogenesis ,Propensity score matching ,Female ,business - Abstract
Although partial nephrectomy (PN) is the standard treatment for localized clinical T1a renal cell carcinoma (RCC), treatment of larger renal tumors is controversial. We evaluated the oncological outcomes and perioperative complications after radical and PN for RCC ≥4cm.We retrospectively analyzed the data of 2,373 patients surgically treated for nonmetastatic RCC with clinical T1b or T2 (≥4cm). The propensity scores for surgery type were calculated, and the partial group was matched to the radical group in a 1:3 ratio. The oncological outcomes were compared using Kaplan-Meier analysis and multivariate Cox regression models were used to identify the independent predictors of progression-free, cancer-specific, and overall survival.All differences in preoperative clinical characteristics disappeared after matching. There were no significant differences in progression-free, cancer-specific, or overall survival between the partial and radical groups in the matched cohort. The patients' age, tumor size, cellular grade, and pathologic stage were independent predictors for all 3 survival outcomes. However, early complications (30d postoperative) were significantly more common in the partial group (P0.001). In a subgroup analysis of the patients with clinical T2 stage, there were no significant differences in all 3 survival outcomes.The partial and radical nephrectomy groups had equivalent oncological outcomes. Although the early complication rate was significantly higher after PN, it should be considered as a valuable treatment option even in patients with clinical T1b or higher RCC.
- Published
- 2017
- Full Text
- View/download PDF
108. Formation of glycine from HCN and H2O: A computational mechanistic study
- Author
-
Hyun Moo Lee and Joong Chul Choe
- Subjects
chemistry.chemical_classification ,Addition reaction ,Ketone ,Hydrogen ,General Physics and Astronomy ,chemistry.chemical_element ,Trimer ,010402 general chemistry ,01 natural sciences ,Medicinal chemistry ,0104 chemical sciences ,Catalysis ,chemistry.chemical_compound ,chemistry ,0103 physical sciences ,Glycine ,Organic chemistry ,Molecule ,Physical and Theoretical Chemistry ,010303 astronomy & astrophysics ,Malononitrile - Abstract
The potential energy surfaces for the formation of glycine from HCN and H2O were determined from CBS-QB3 calculations. After the formation of a HCN trimer, amino malononitrile, amino malononitrile monoamide (3) was formed by a water addition reaction. Two pathways were found for the subsequent reaction, 3 + 2H2O → glycine + HNCO + NH3. One pathway involving an amino ketone was much more favored than the other pathway involving glycinamide. Addition of a water molecule as a catalyst greatly enhanced steps occurring by hydrogen rearrangement.
- Published
- 2017
- Full Text
- View/download PDF
109. Postoperative Outcome of Cystic Renal Cell Carcinoma Defined on Preoperative Imaging: A Retrospective Study
- Author
-
Jung Jae Park, Han Yong Choi, Hyun Moo Lee, Keumhee C. Carriere, Byong Chang Jeong, Chan Kyo Kim, Min-Ji Kim, Byung Kwan Park, Seong Soo Jeon, and Seong Il Seo
- Subjects
medicine.medical_specialty ,Proportional hazards model ,business.industry ,Urology ,030232 urology & nephrology ,Cancer ,Retrospective cohort study ,Institutional review board ,medicine.disease ,Preoperative care ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,Renal cell carcinoma ,Informed consent ,030220 oncology & carcinogenesis ,medicine ,Carcinoma ,Radiology ,business - Abstract
Purpose: We evaluated the postoperative outcome of cystic renal cell carcinoma defined on preoperative computerized tomography. We also sought to find the optimal cutoff of the cystic proportion in association with patient prognosis.Material and Methods: In this institutional review board approved study with waiver of informed consent, 1,315 patients were enrolled who underwent surgery for a single renal cell carcinoma with preoperative computerized tomography. The cystic proportion of renal cell carcinoma was determined on computerized tomography. The optimal cutoff of the cystic proportion was explored regarding cancer specific survival. Renal cell carcinomas were categorized as cystic or noncystic renal cell carcinoma according to a conventional cutoff (ie cystic proportion 75% or greater) and an optimal cutoff. Postoperative outcomes were then compared between the 2 groups. Multivariate Cox regression analysis was performed to determine the independent predictor of cancer specific survival.Results: Of...
- Published
- 2017
- Full Text
- View/download PDF
110. Re-stratification of Patients with High-Risk Prostate Cancer According to the NCCN Guidelines among Patients Who Underwent Radical Prostatectomy: An Analysis Based on the K-CaP Registry
- Author
-
Seok-Soo Byun, Ji Youl Lee, Byung Ha Chung, Sung Kyu Hong, Hyun Moo Lee, Koon Ho Rha, Choung Soo Kim, Jun Hyuk Hong, Kyo Chul Koo, In Young Choi, and Kwang Suk Lee
- Subjects
Biochemical recurrence ,Oncology ,Male ,Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,Databases, Factual ,medicine.medical_treatment ,030232 urology & nephrology ,Risk Assessment ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Risk groups ,Risk Factors ,Internal medicine ,Biopsy ,medicine ,Humans ,Registries ,Prostatectomy ,medicine.diagnostic_test ,business.industry ,Significant difference ,Prostatic Neoplasms ,Middle Aged ,medicine.disease ,030220 oncology & carcinogenesis ,Original Article ,Risk assessment ,business - Abstract
Purpose The present study aimed to re-stratify patients with high-risk prostate cancer according to the National Comprehensive Cancer Network guidelines among patients who underwent radical prostatectomy (RP). Materials and Methods This study used the Korean Prostate Cancer Database registry and identified 1,060 patients with high-risk prostate cancer who underwent RP between May 2001 and April 2013. All patients were categorized into risk groups, and subgroups were identified according to the type and number of high-risk factors. Results Of the 1,060 high-risk patients, 599 (56.5%), 408 (38.5%), and 53 (5.0%) had 1, 2, and 3 risk factors, respectively. In multivariate analysis, the Gleason score, percentage of positive biopsy cores, and number of risk factors present were identified as independent predictors of biochemical recurrence. There were significant differences in the 5-year postoperative biochemical failure-free survival (BCFFS) rate among the different high-risk factor subgroups (log-rank p < 0.001). There were no significant differences in the BCFFS rate between the subgroup of high-risk patients with a prostate-specific antigen level > 20 ng/mL alone and the intermediate-risk group with all factors (log-rank p=0.919 and p=0.781, respectively). Additionally, no significant difference was noted in the BCFFS rate between high-risk patients having all factors and those in the very-high-risk group (p=0.566). Conclusion We successfully re-stratified patients with high-risk prostate cancer and identified the combinations of high-risk criteria that will help in the selection of patients for RP.
- Published
- 2017
111. Strategy for Prostate Cancer Patients with Low Prostate Specific Antigen Level (2.5 to 4.0 ng/mL)
- Author
-
Hyun Moo Lee, Wan Song, Hyun Hwan Sung, Byong Chang Jeong, Jae Hoon Chung, Minyong Kang, Jiwoong Yu, Seong Il Seo, Seong Soo Jeon, and Hwang Gyun Jeon
- Subjects
Male ,medicine.medical_specialty ,Prostate biopsy ,Urology ,Biopsy ,medicine.medical_treatment ,Comorbidity ,urologic and male genital diseases ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Risk Factors ,Prostate ,Diagnosis ,Humans ,Medicine ,030212 general & internal medicine ,Aged ,Retrospective Studies ,medicine.diagnostic_test ,business.industry ,Prostatectomy ,Prostatic Neoplasms ,Cancer ,General Medicine ,Middle Aged ,Prostate-Specific Antigen ,medicine.disease ,Prostate-specific antigen ,medicine.anatomical_structure ,ROC Curve ,Area Under Curve ,Baseline characteristics ,Original Article ,Neoplasm Grading ,business - Abstract
Background To evaluate the strategy for detection of prostate cancer (PCa) with low prostate specific antigen (PSA) level (2.5–4.0 ng/mL), prostate biopsy patients with low PSA were assessed. We evaluated the risk of low PSA PCa and the strategy for screening low-PSA patients. Methods We retrospectively analyzed the patients who underwent prostate biopsy with low PSA level. Baseline characteristics, PSA level before prostate biopsy, prostate volume, prostate specific antigen density (PSAD), and pathological data were assessed. Results Among the 1986 patients, 24.97% were diagnosed with PCa. The PSAD was 0.12 ± 0.04 ng/mL2 in the PCa-diagnosed group and 0.10 ± 0.04 ng/mL2 in non-cancer-diagnosed group (P < 0.001). Of the 496 patients diagnosed with PCa, 302 (60.89%) were in the intermediate- or high-risk group. PSAD was 0.13 ± 0.04 ng/mL2 in the intermediate- or high-risk group and 0.11 ± 0.03 ng/mL2 in the very low- and low-risk group (P < 0.001). Of 330 patients who underwent radical prostatectomy, 85.15% were diagnosed as having significant cancer. There was significant correlation between PSAD and PCa (r = 0.294, P < 0.001). PSAD with a specificity of 80.00% of a clinically significant cancer diagnosis was assessed at 0.1226 ng/mL2. Conclusion The PCa detection rate in the low-PSA group was not lower than that of previous studies of patients with PSA from 4.0 to 10.0 ng/mL. Further, it may be helpful to define a strategy for PCa detection using PSAD in the low-PSA group., Graphical Abstract
- Published
- 2020
- Full Text
- View/download PDF
112. Comparison by Pentafecta Criteria of Transperitoneal and Retroperitoneal Robotic Partial Nephrectomy for Large Renal Tumors
- Author
-
Hyun Moo Lee, Seong Il Seo, Hyun Hwan Sung, Byong Chang Jeong, Hwang Gyun Jeon, Seong Soo Jeon, Minyong Kang, and Chang Il Choi
- Subjects
Adult ,Male ,medicine.medical_specialty ,Urology ,medicine.medical_treatment ,Operative Time ,030232 urology & nephrology ,Nephrectomy ,03 medical and health sciences ,0302 clinical medicine ,Robotic Surgical Procedures ,TRPN ,Medicine ,Humans ,Postoperative Period ,Retroperitoneal Space ,Warm Ischemia ,Renal Insufficiency, Chronic ,Retrospective Studies ,Surgeons ,business.industry ,technology, industry, and agriculture ,Margins of Excision ,Middle Aged ,Kidney Neoplasms ,body regions ,surgical procedures, operative ,Nephrology ,030220 oncology & carcinogenesis ,Female ,Neoplasm Recurrence, Local ,business ,human activities ,Glomerular Filtration Rate - Abstract
Objective: To compare and analyze surgical and functional outcomes of transperitoneal robotic partial nephrectomy (TRPN) and retroperitoneal robotic partial nephrectomy (RRPN) in localized renal tu...
- Published
- 2019
113. Transperitoneal radical nephroureterectomy is associated with worse disease progression than retroperitoneal radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma
- Author
-
Hwang Gyun Jeon, Hyun Moo Lee, Byong Chang Jeong, Hyun Hwan Sung, Tae Heon Kim, Seong Soo Jeon, Han Yong Choi, Yoon Seok Suh, and Seong Il Seo
- Subjects
Male ,0301 basic medicine ,Urologic Neoplasms ,medicine.medical_specialty ,Urology ,lcsh:Medicine ,Nephroureterectomy ,Article ,03 medical and health sciences ,0302 clinical medicine ,Carcinoma ,Humans ,Medicine ,lcsh:Science ,Urinary Tract ,Pathological ,Survival rate ,Aged ,Proportional Hazards Models ,Retrospective Studies ,Upper urinary tract ,Carcinoma, Transitional Cell ,Multidisciplinary ,business.industry ,Proportional hazards model ,lcsh:R ,Retrospective cohort study ,Urological manifestations ,Middle Aged ,Prognosis ,medicine.disease ,Survival Rate ,030104 developmental biology ,Urinary tract surgery ,T-stage ,lcsh:Q ,Female ,Laparoscopy ,Ureter ,Urothelium ,business ,030217 neurology & neurosurgery - Abstract
This study aimed to compare the oncologic outcomes between retroperitoneal radical nephroureterectomy (rRNU) and transperitoneal radical nephroureterectomy (tRNU) for the treatment of patients with upper urinary tract urothelial carcinoma (UTUC). Medical records of 743 eligible patients who underwent rRNU or tRNU between 1995 and 2015 were reviewed retrospectively. Progression-free survival (PFS), cancer-specific survival (CSS), and overall survival (OS) were compared according to the surgical approach using the Kaplan–Meier method. Predictors of PFS, CSS, and OS were analyzed with a multivariable Cox regression model. Overall, 620 (83.4%) and 123 (16.6%) patients were treated with rRNU and tRNU, respectively. Five-year CSS and OS rates were equivalent between rRNU and tRNU groups, but 5-year PFS was lower in the tRNU group than the rRNU group (P = 0.005). When patients were stratified by pathological T stage, PFS was significantly different between the two groups in favor of the rRNU group for both organ-confined disease (pTis/pTa/pT1/T2) (P = 0.022) and locally advanced disease (pT3/pT4) (P = 0.039). However, no significant differences in CSS or OS was observed when comparing the two surgical types in patients with organ-confined disease (P = 0.336 and P = 0.851) or patients with locally advanced disease (P = 0.499 and P = 0.278). tRNU was a significant predictor of PFS (hazard ratio = 1.54; P = 0.023), but not CSS or OS. Our findings indicate that the rRNU approach resulted in better PFS than the tRNU approach in patients with UTUC.
- Published
- 2019
- Full Text
- View/download PDF
114. MP31-17 COMPARISON OF RETROPERITONEAL AND TRANSPERITONEAL ROBOTIC PARTIAL NEPHRECTOMY BY PENTAFECTA PERIOPERATIVE AND RENAL FUNCTIONAL OUTCOMES
- Author
-
Byong Chang Jeong, Hwang Gyun Jeon, Young Hyo Choi, Hyun Hwan Sung, Jiwoong Yu, Hyun Moo Lee, Seong Soo Jeon, C. Choi, Seong Il Seo, and Minyong Kang
- Subjects
medicine.medical_specialty ,business.industry ,Urology ,medicine.medical_treatment ,TRPN ,medicine ,Perioperative ,business ,Nephrectomy ,Surgery - Abstract
INTRODUCTION AND OBJECTIVES:To compare and analyze surgical, oncological and functional outcomes of transperitoneal robotic partial nephrectomy (TRPN) and retroperitoneal RPN (RRPN).METHODS:Out of ...
- Published
- 2019
- Full Text
- View/download PDF
115. Novel Predictive Models of Early Death Less Than 1 Year in Patients With Metastatic Renal Cell Carcinoma After Treatment With First-line Tyrosine Kinase Inhibitors
- Author
-
Hyun Hwan Sung, Hwang Gyun Jeon, Seong Soo Jeon, Minyong Kang, Se Hoon Park, Seong Il Seo, Hyun Moo Lee, Han Yong Choi, Seung Jea Shin, Tae Jin Kim, and Byong Chang Jeong
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Time Factors ,Databases, Factual ,medicine.drug_class ,Neutrophils ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Serum Albumin, Human ,Kaplan-Meier Estimate ,Logistic regression ,Nephrectomy ,Risk Assessment ,Tyrosine-kinase inhibitor ,Body Mass Index ,03 medical and health sciences ,Hemoglobins ,Leukocyte Count ,0302 clinical medicine ,Renal cell carcinoma ,Risk Factors ,Internal medicine ,medicine ,Clinical endpoint ,Humans ,Carcinoma, Renal Cell ,Protein Kinase Inhibitors ,Aged ,Retrospective Studies ,business.industry ,Metastasectomy ,Middle Aged ,medicine.disease ,Kidney Neoplasms ,Nomograms ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Female ,business ,Tyrosine kinase ,Body mass index - Abstract
Background We aimed to develop a modified International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model that can predict early death less than 1 year in patients with metastatic renal cell carcinoma (mRCC) after receiving first-line tyrosine kinase inhibitors (TKIs). Patients and Methods We retrospectively reviewed records of patients with mRCC treated with first-line TKIs at our institution between 2007 and 2012. The primary endpoint was the rate of early death within 1 year after first-line TKI administration. We determined statistically significant factors predicting early death by performing multiple logistic regression. The modified IMDC model 1 was developed using new variables in addition to the risk criteria of the IMDC model, and model 2 was developed using new variables irrespective of the risk classification of IMDC model. Results Early mortality within 1 year of first-line TKI treatment was 19.7% (n = 98) in 462 patients. Although the C-index of the IMDC model for early death was 0.655, the C-index of model 1, which includes 5 variables (previous nephrectomy, body mass index, multiple metastases, previous metastasectomy, and serum albumin level) in addition to the Heng criteria, was 0.823. The C-index of model 2, which includes 7 variables (hemoglobin, neutrophil level, and the 5 variables of model 1) was 0.822. Of note, there was no significant difference in net reclassification index between the 2 models. Conclusion This is the first study suggesting novel prediction models for early death less than 1 year in patients with mRCC treated with first-line TKI.
- Published
- 2019
116. Risk Factors and Patterns of Locoregional Recurrence after Radical Nephrectomy for Locally Advanced Renal Cell Carcinoma.
- Author
-
Gyu Sang Yoo, Won Park, Hongryull Pyo, Byong Chang Jeong, Hwang Gyun Jeon, Minyong Kang, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi, Byung Kwan Park, Chan Kyo Kim, Sung Yoon Park, and Ghee Young Kwon
- Subjects
RENAL cell carcinoma ,NEPHRECTOMY ,VENA cava inferior ,MESENTERIC artery ,KIDNEY tumors - Abstract
Purpose We aimed to investigate the risk factors and patterns of locoregional recurrence (LRR) after radical nephrectomy (RN) in patients with locally advanced renal cell carcinoma (RCC). Materials and Methods We retrospectively analyzed 245 patients who underwent RN for non-metastatic pT3-4 RCC from January 2006 to January 2016. We analyzed the risk factors associated with poor locoregional control using Cox regression. Anatomical mapping was performed on reference computed tomography scans showing intact kidneys. Results The median follow-up duration was 56 months (range, 1 to 128 months). Tumor extension to renal vessels or the inferior vena cava (IVC) and Fuhrman's nuclear grade IV were identified as independent risk factors of LRR. The 5-year actuarial LRR rates in groups with no risk factor, one risk factor, and two risk factors were 2.3%, 19.8%, and 30.8%, respectively (p < 0.001). The locations of LRR were distributed as follows: aortocaval area (n=2), paraaortic area (n=4), retrocaval area (n=5), and tumor bed (n=11). No LRR was observed above the celiac axis (CA) or under the inferior mesenteric artery (IMA). Conclusion Tumor extension to renal vessels or the IVC and Fuhrman's nuclear grade IV were the independent risk factors associated with LRR after RN for pT3-4 RCC. The locations of LRR after RN for RCC were distributed in the tumor bed and regional lymphatic area from the bifurcation of the CA to that of the IMA. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
117. Mutation of MED12 is not a frequent occurrence in prostate cancer of Korean patients
- Author
-
So Young Kang, Ghee Young Kwon, Byong Chang Jeong, Nara Yoon, Han Yong Choi, Seong Il Seo, Hyun Moo Lee, Hwang Gyun Jeon, Seong Soo Jeon, and Sharon Lim
- Subjects
0301 basic medicine ,Urology ,medicine.medical_treatment ,Bioinformatics ,lcsh:RC870-923 ,03 medical and health sciences ,symbols.namesake ,Prostate cancer ,0302 clinical medicine ,medicine ,mediator complex subunit 12 ,mutation analysis ,prostate cancer ,prostate neoplasms ,Allele frequency ,Exome sequencing ,Sanger sequencing ,Prostatectomy ,business.industry ,General Medicine ,medicine.disease ,lcsh:Diseases of the genitourinary system. Urology ,030104 developmental biology ,030220 oncology & carcinogenesis ,Mutation (genetic algorithm) ,symbols ,Mutation testing ,Prostate neoplasm ,business - Abstract
Prostate cancer is one of the major health care problems, but the molecular pathogenesis has been relatively insufficiently elucidated. Recently, whole exome sequencing of prostate cancer identified recurrent mutations involving MED12 in Caucasian patients, which finding was not reproduced in one subsequent study by Sanger sequencing. Thus, we investigated mutation status of MED12 in exons 2 and 26 by Sanger sequencing in 102 radical prostatectomy cases from Korean patients. The analysis found the mutation in none of the cases. Therefore, MED12 mutation does not appear to represent a significant molecular alteration in this cohort of patients according to the analysis by the traditional "gold standard."
- Published
- 2017
118. Comparisons between Standard and Extended Pelvic Lymph Node Dissections During Radical Cystectomy in Patients with Bladder Cancer: Emphasis on Staging Ability and Perioperative Complications
- Author
-
Hakmin Lee, Hyun Hwan Sung, Hyun Moo Lee, Seong Il Seo, Sang-Eun Lee, Seong Soo Jeon, Byong Chang Jeong, and Han-Yong Choi
- Subjects
medicine.medical_specialty ,Bladder cancer ,business.industry ,General surgery ,medicine.medical_treatment ,030232 urology & nephrology ,Perioperative ,medicine.disease ,Cystectomy ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,medicine ,In patient ,business ,Lymph node - Published
- 2016
- Full Text
- View/download PDF
119. Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer
- Author
-
Byong Chang Jeong, Hwang Gyun Jeon, Ghee Young Kwon, Han Yong Choi, Jeong Hoon Kim, Wan Song, Seong Soo Jeon, Joung Eun Lim, Hyun Moo Lee, and Seong Il Seo
- Subjects
Male ,0301 basic medicine ,Pathology ,Time Factors ,Biopsy ,Docetaxel ,Kaplan-Meier Estimate ,Gastroenterology ,Prostate cancer ,0302 clinical medicine ,Risk Factors ,Neoplasm Metastasis ,Transcriptional Regulator ERG ,Aged, 80 and over ,Tissue microarray ,medicine.diagnostic_test ,SOX9 Transcription Factor ,Middle Aged ,prostate cancer ,Immunohistochemistry ,Prostatic Neoplasms, Castration-Resistant ,Prostate-specific antigen ,Treatment Outcome ,Oncology ,ERG ,030220 oncology & carcinogenesis ,Disease Progression ,biomarker ,Kallikreins ,Taxoids ,Erg ,SOX9 ,Research Paper ,medicine.drug ,medicine.medical_specialty ,Antineoplastic Agents ,Disease-Free Survival ,03 medical and health sciences ,Predictive Value of Tests ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Aged ,Proportional Hazards Models ,Retrospective Studies ,business.industry ,Prostate-Specific Antigen ,medicine.disease ,030104 developmental biology ,Tissue Array Analysis ,business - Abstract
We aimed to evaluate ERG and SOX9 as potential biomarkers of docetaxel response in metastatic castration-resistant prostate cancer (mCRPC) patients. Seventy-one mCRPC patients were evaluated. Tissue microarrays were constructed and immunohistochemistry was performed. Treatment response was assessed by prostate specific antigen (PSA) response rate, PSA progression-free survival (PSA-PFS), clinical/radiologic PFS (C/R-PFS) and overall survival (OS). ERG and SOX9 were found in 13 (18.3%) and 62 (87.3%) patients, respectively. ERG-positive had lower PSA response rates than negative (15.4% vs 62.1%, p = 0.004), and SOX9 showed a same trend (46.8% vs 100.0%, p = 0.003). ERG positivity correlated with a lower PSA-PFS (3.2 mos vs 7.4 mos, p < 0.001), C/R-PFS (3.8 mos vs 9.0 mos, p < 0.001) and OS (10.8 mos vs 21.4 mos, p < 0.001). SOX9 positivity also showed a lower PSA-PFS, C/R-PFS and OS (p =0.006, p =0.012 and p =0.023, respectively). On multivariate analysis, ERG positivity was a significant risk factor for a lower PSA-PFS, C/R-PFS and OS (p < 0.001, p < 0.001 and p =0.001, respectively). SOX9 expression was also a risk factor for a lower PSA-PFS, C/R-PFS and OS (p = 0.018, p = 0.025 and p =0.047, respectively). These findings indicate that ERG and SOX9 is potential biomarkers for prediction to docetaxel treatment in mCRPC patients.
- Published
- 2016
- Full Text
- View/download PDF
120. Accuracy of preoperative multiparametric magnetic resonance imaging for prediction of unfavorable pathology in patients with localized prostate cancer undergoing radical prostatectomy
- Author
-
Hakmin Lee, Deok Hyun Han, Byung Kwan Park, Hwang Gyun Jeon, Hyun Hwan Sung, Byong Chang Jeong, Chan Kyo Kim, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, and Han Yong Choi
- Subjects
Adult ,Male ,Biochemical recurrence ,medicine.medical_specialty ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Kaplan-Meier Estimate ,Risk Assessment ,Disease-Free Survival ,Cohort Studies ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Predictive Value of Tests ,Prostate ,Preoperative Care ,Republic of Korea ,medicine ,Humans ,Neoplasm Invasiveness ,Multiparametric Magnetic Resonance Imaging ,Aged ,Neoplasm Staging ,Retrospective Studies ,Prostatectomy ,medicine.diagnostic_test ,business.industry ,Prostatic Neoplasms ,Cancer ,Magnetic resonance imaging ,Middle Aged ,Prognosis ,medicine.disease ,Neurovascular bundle ,Magnetic Resonance Imaging ,Survival Analysis ,Logistic Models ,Treatment Outcome ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Multivariate Analysis ,Radiology ,business - Abstract
We investigated the accuracy of multiparametric MRI (mpMRI) for preoperative staging and its influence on the determination of neurovascular bundle sparing and disease prognosis in patients with localized prostate cancer. We reviewed 1045 patients who underwent radical prostatectomy with preoperative mpMRI at a single institution. Clinical local stages determined from mpMRI were correlated with preoperative and postoperative pathological outcomes. The sensitivity and specificity to diagnose seminal vesicle invasion (SVI) on mpMRI were 43.8 and 95.4 %, respectively. The negative predictive value was 78.9 %. The sensitivity and specificity to diagnose extracapsular extension (ECE) were 54.5 and 80.5 %, respectively. The overall sensitivity and specificity of diagnosing pathological T3 or higher were 52.6 and 82.1 %, respectively. Non-organ-confined disease determined by mpMRI was significantly associated with positive surgical margin and pathological T3 disease on multivariate analysis. Preoperative adverse findings on mpMRI were significantly associated with performance of the non-nerve-sparing technique. mpMRI did not show outstanding diagnostic accuracy relative to our expectations in predicting SVI or ECE preoperatively. However, adverse findings on preoperative mpMRI were significantly related to worse postoperative pathological outcomes as well as postoperative biochemical recurrence.
- Published
- 2016
- Full Text
- View/download PDF
121. Curcumin potentiates antitumor activity of cisplatin in bladder cancer cell lines via ROS-mediated activation of ERK1/2
- Author
-
Bong Hee Park, Seong Il Seo, Byong Chang Jeong, Han Yong Choi, Hwang Gyun Jeon, Joung Eun Lim, Seong Soo Jeon, and Hyun Moo Lee
- Subjects
0301 basic medicine ,MAPK/ERK pathway ,cisplatin ,Apoptosis ,medicine.disease_cause ,Mice ,chemistry.chemical_compound ,0302 clinical medicine ,oxidative stress ,Enzyme Inhibitors ,Extracellular Signal-Regulated MAP Kinases ,STAT3 ,chemistry.chemical_classification ,Mice, Inbred BALB C ,biology ,Caspase 3 ,Drug Synergism ,Up-Regulation ,ERK ,Oncology ,030220 oncology & carcinogenesis ,bladder cancer ,Female ,Research Paper ,Signal Transduction ,medicine.drug ,Curcumin ,Mice, Nude ,Antineoplastic Agents ,03 medical and health sciences ,Downregulation and upregulation ,Cell Line, Tumor ,Nitriles ,Butadienes ,medicine ,Animals ,Humans ,Cisplatin ,Reactive oxygen species ,business.industry ,Enzyme Activation ,030104 developmental biology ,Urinary Bladder Neoplasms ,chemistry ,Immunology ,Cancer research ,biology.protein ,Tumor Suppressor Protein p53 ,Reactive Oxygen Species ,business ,Oxidative stress - Abstract
// Bong Hee Park 3 , Joung Eun Lim 2 , Hwang Gyun Jeon 1 , Seong Il Seo 1 , Hyun Moo Lee 1 , Han Yong Choi 1 , Seong Soo Jeon 1 , Byong Chang Jeong 1 1 Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea 2 Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Republic of Korea 3 Department of Urology, Uijeongbu St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea Correspondence to: Seong Soo Jeon, email: seongsoo.jeon@samsung.com Byong Chang Jeong, email: bc2.jung@samsung.com Keywords: bladder cancer, cisplatin, curcumin, ERK, oxidative stress Received: May 11, 2016 Accepted: August 11, 2016 Published: August 24, 2016 ABSTRACT Resistance of bladder cancer to cisplatin is a major obstacle to successful treatment. In the current study, we investigated the apoptotic effects of curcumin and cisplatin co-treatment in 253J-Bv(p53 wild-type) and T24(p53 mutant) bladder cancer. We found that curcumin and cisplatin co-treatment primarily targets reactive oxygen species(ROS) and extracellular regulated kinase(ERK) signaling during the apoptosis induction in bladder cancer. The apoptosis rate in 253J-Bv and T24 cells co-treated with curcumin and cisplatin was increased compared to that in cells exposed to single-agent treatment conditions. Also, caspase-3 activation and ROS production were observed in both cells treated with curcumin and cisplatin, together with upregulation of p-MEK and p-ERK1/2 signaling. NAC(ROS scavenger) and U0126(ERK inhibitor) inhibited apoptosis induced by curcumin and cisplatin. In addition, when 253J-Bv cells were co-treated with curcumin and cisplatin, p53 and p21 expression levels were markedly increased when compared to controls. Unlike 253J-Bv cells, T24 cells were co-treated with curcumin and cisplatin revealed an induction of apoptosis through decreased p-signal transducer and activator of transcription 3(STAT3) expression. Moreover, pretreatment with U0126 suppressed curcumin and cisplatin-induced upregulation of p53, p21, and p-STAT3 and downregulation of survival proteins in both cells. In conclusion, co-treatment with curcumin and cisplatin synergistically induced apoptosis through ROS-mediated activation of ERK1/2 in bladder cancer.
- Published
- 2016
- Full Text
- View/download PDF
122. Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion
- Author
-
Hye Jin Song, Do-Hyun Nam, Joung Eun Lim, Hyun Hwan Sung, Han-Yong Choi, Nakho Chang, Hye Won Lee, Da Eun Jeong, Hwang Gyun Jeon, Seong Il Seo, Sudong Kim, Hyun Moo Lee, Seong Soo Jeon, and Byong Chang Jeong
- Subjects
Male ,0301 basic medicine ,Oncology ,PTEN ,Pathology ,medicine.medical_specialty ,patient-derived xenograft ,EGFR ,Primary Cell Culture ,Dasatinib ,Antineoplastic Agents ,muscle invasive bladder cancer ,Metastasis ,03 medical and health sciences ,0302 clinical medicine ,Cell Line, Tumor ,Internal medicine ,medicine ,Humans ,Neoplasm Invasiveness ,EGFR Gene Amplification ,drug screening ,Epidermal growth factor receptor ,PI3K/AKT/mTOR pathway ,Carcinoma, Transitional Cell ,Muscle Neoplasms ,Bladder cancer ,biology ,business.industry ,Gene Amplification ,PTEN Phosphohydrolase ,Middle Aged ,medicine.disease ,ErbB Receptors ,030104 developmental biology ,Urinary Bladder Neoplasms ,030220 oncology & carcinogenesis ,Concomitant ,Mutation ,biology.protein ,Drug Screening Assays, Antitumor ,business ,Gene Deletion ,Research Paper ,medicine.drug - Abstract
// Nakho Chang 1, 2, 3, * , Hye Won Lee 3, 4, * , Joung Eun Lim 5 , Da Eun Jeong 1 , Hye Jin Song 6 , Sudong Kim 3, 7 , Do-Hyun Nam 1, 2, 3 , Hyun Hwan Sung 5 , Byong Chang Jeong 5 , Seong Il Seo 5 , Seong Soo Jeon 5 , Hyun Moo Lee 5 , Han-Yong Choi 5 , Hwang Gyun Jeon 5 1 Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul 06351, Korea 2 Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea 3 Institute for Refractory Cancer Research, Samsung Medical Center, Seoul 06351, Korea 4 Institute for Future Medicine, Samsung Medical Center, Seoul 06351, Korea 5 Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea 6 Department of Anatomy and Cell Biology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea 7 Samsung Advanced Institute of Technology, Samsung Electronics Co., Ltd., Seoul 06351, Korea * These authors contributed equally to this work Correspondence to: Hwang Gyun Jeon, email: hwanggyun.jeon@samsung.com Keywords: muscle invasive bladder cancer, PTEN, EGFR, drug screening, patient-derived xenograft Received: May 20, 2016 Accepted: June 29, 2016 Published: July 12, 2016 ABSTRACT Muscle-invasive bladder cancer (MIBC) consists of a heterogeneous group of tumors with a high rate of metastasis and mortality. To facilitate the in-depth investigation and validation of tailored strategies for MIBC treatment, we have developed an integrated approach using advanced high-throughput drug screening and a clinically relevant patient-derived preclinical platform. We isolated patient-derived tumor cells (PDCs) from a rare MIBC case (BD-138T) that harbors concomitant epidermal growth factor receptor (EGFR) amplification and phosphatase and tensin homolog (PTEN) deletion. High-throughput in vitro drug screening demonstrated that dasatinib, a SRC inhibitor, and PKI-587, a dual PI3K/mTOR inhibitor, exhibited targeted anti-proliferative and pro-apoptotic effects against BD-138T PDCs. Using established patient-derived xenograft models that successfully retain the genomic and molecular characteristics of the parental tumor, we confirmed that these anti-tumor responses occurred through the inhibition of SRC and PI3K/AKT/mTOR signaling pathways. Taken together, these experimental results demonstrate that dasatinib and PKI-587 might serve as promising anticancer drug candidates for treating MIBC with combined EGFR gene amplification and PTEN deletion.
- Published
- 2016
- Full Text
- View/download PDF
123. The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients
- Author
-
Young Deuk Choi, Sang Eun Lee, Choung Soo Kim, Dong Deuk Kwon, Byung Ha Chung, Kang Hyun Lee, Hyun Moo Lee, and Ad Theeuwes
- Subjects
0301 basic medicine ,Oncology ,Male ,Urological Oncology ,Administration, Oral ,lcsh:RC870-923 ,Androgen deprivation therapy ,chemistry.chemical_compound ,Prostate cancer ,0302 clinical medicine ,Antineoplastic agents ,Antineoplastic Combined Chemotherapy Protocols ,Aged, 80 and over ,Hazard ratio ,Middle Aged ,Prostate-specific antigen ,Prostatic Neoplasms, Castration-Resistant ,Treatment Outcome ,030220 oncology & carcinogenesis ,Benzamides ,Disease Progression ,Original Article ,Kallikreins ,Adult ,medicine.medical_specialty ,Antineoplastic Agents, Hormonal ,Disease-free survival ,Urology ,Castration-resistant prostatic neoplasms ,MDV 3100 ,Republic of Korea ,Adenocarcinoma ,Placebo ,03 medical and health sciences ,Double-Blind Method ,Internal medicine ,Nitriles ,Phenylthiohydantoin ,medicine ,Enzalutamide ,Humans ,Survival analysis ,Aged ,business.industry ,Prostate-Specific Antigen ,lcsh:Diseases of the genitourinary system. Urology ,medicine.disease ,Survival Analysis ,Discontinuation ,Surgery ,Radiography ,030104 developmental biology ,chemistry ,business - Abstract
Purpose: This post hoc analysis evaluated treatment effects, safety, and pharmacokinetics of enzalutamide in Korean patients in the phase 3, double-blind, placebo-controlled PREVAIL trial. Materials and Methods: Asymptomatic or mildly symptomatic chemotherapy-naïve men with metastatic castration-resistant prostate cancer that progressed on androgen deprivation therapy received 160 mg/d oral enzalutamide or placebo (1:1) until death or discontinuation due to radiographic progression or skeletal-related event and initiation of subsequent therapy. Coprimary end points were centrally assessed radiographic progression-free survival (rPFS) and overall survival (OS). Secondary end points included investigator-assessed rPFS, time to initiation of chemotherapy, time to prostate-specific antigen (PSA) progression, PSA response (≥50% decline), and time to skeletal-related event. Results: Of 1,717 total patients, 78 patients were enrolled in Korea (enzalutamide, n=40; placebo, n=38). Hazard ratios (95% confidence interval) for enzalutamide versus placebo were 0.23 (0.02–2.24) for centrally assessed rPFS, 0.77 (0.28–2.15) for OS, 0.21 (0.08–0.51) for time to chemotherapy, and 0.31 (0.17–0.56) for time to PSA progression. A PSA response was observed in 70.0% of enzalutamide-treated and 10.5% of placebo-treated Korean patients. Adverse events of grade ≥3 occurred in 33% of enzalutamide- treated and 11% of placebo-treated Korean patients, with median treatment durations of 13.0 and 5.1 months, respectively. At 13 weeks, the plasma concentration of enzalutamide plus N-desmethyl enzalutamide was similar in Korean and non-Korean patients (geometric mean ratio, 1.04; 90% confidence interval, 0.97–1.10). Conclusions: In Korean patients, treatment effects and safety of enzalutamide were consistent with those observed in the overall PREVAIL study population (ClinicalTrials.gov Identifier: NCT01212991).
- Published
- 2016
124. Size and Volumetric Growth Kinetics of Renal Masses in Patients With Renal Cell Carcinoma
- Author
-
Han-Yong Choi, Hwang Gyun Jeon, Hyun Hwan Sung, Sin Woo Lee, Byong Chang Jeong, Seong Soo Jeon, Hyun Moo Lee, and Seong Il Seo
- Subjects
medicine.medical_specialty ,business.industry ,Urology ,Volume Doubling Time ,Volumetric growth ,030232 urology & nephrology ,Retrospective cohort study ,Odds ratio ,medicine.disease ,Confidence interval ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,Renal cell carcinoma ,030220 oncology & carcinogenesis ,Carcinoma ,Medicine ,Risk factor ,business - Abstract
Objective To examine radiological growth patterns as an indicator of renal tumor aggressiveness, we studied about the growth kinetics of small renal mass (SRM, ≤4 cm) and possible associated factors for high Fuhrman nuclear grade (≥3). Materials and Methods From January 1999 to May 2013, 112 cases (111 patients) diagnosed as renal cell carcinoma after surgical treatment were reviewed retrospectively. Patients who had at least two preoperative contrast-enhanced computed tomography scans more than 6 months apart were included. Results The mean age was 59 years and mean computed tomography follow-up duration was 20 months. Median tumor size and tumor volume at diagnosis were 1.45 cm and 1.80 cm 3 , respectively. Median linear growth rate (LGR) was 0.28 cm/year. Median volumetric growth rate was 0.75 cm 3 /year and median volume doubling time was 1.41 years. Tumor growth rate was not different to histologic type ( P = .271). High LGR was a significant factor associated with high Fuhrman grade in multivariate analysis (odds ratio 3.877, 95% confidence interval 1.715-8.765). Volumetric growth rate ( P .001) and volume doubling time ( P = .004) were positive correlation with initial mass size, but not LGR (P = .764). Conclusion In our growth kinetics study, generally small renal mass grew slowly. High LGR could be a risk factor for high-grade tumor (Fuhrman grade ≥3).
- Published
- 2016
- Full Text
- View/download PDF
125. Comparison of preoperative adaptive enlargement of the contralateral normal kidney in patients nephrectomized for benign non-functioning kidney versus renal cell carcinoma
- Author
-
Hyun Moo Lee, Seong Soo Jeon, Han Yong Choi, Deok Hyun Han, Seong Il Seo, Byong Chang Jeong, Hyun Hwan Sung, Hwang Gyun Jeon, and Wan Song
- Subjects
medicine.medical_specialty ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Renal function ,Kidney Volume ,Computed tomography ,Kidney ,Nephrectomy ,03 medical and health sciences ,0302 clinical medicine ,Renal cell carcinoma ,Preoperative Care ,medicine ,Humans ,In patient ,Carcinoma, Renal Cell ,Retrospective Studies ,medicine.diagnostic_test ,business.industry ,medicine.disease ,Kidney Neoplasms ,Surgery ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,business ,Glomerular Filtration Rate ,Kidney disease - Abstract
Objectives To investigate the potential effects of preoperative volumetric compensation of the contralateral normal kidney on renal function after simple nephrectomy or radical nephrectomy. Methods A total of 306 patients (80 simple nephrectomy patients and 226 radical nephrectomy patients) with 1:3 propensity score matching were included between October 1996 and December 2013. Preoperative three-dimensional kidney volume was estimated from computed tomography images using a specialized volumetric program. Glomerular filtration rate assessed using the Chronic Kidney Disease Epidemiology Collaboration equations was checked preoperatively, 1 week, 3 months and 1 year after nephrectomy. Results Preoperative mean Chronic Kidney Disease Epidemiology Collaboration glomerular filtration rate was 76.5 mL/min/1.73 m2 in the simple nephrectomy group and 89.2 mL/min/1.73 m2 in the radical nephrectomy group. In simple nephrectomy patients, mean Chronic Kidney Disease Epidemiology Collaboration glomerular filtration rate showed a stable pattern up to 3 months (75.5 mL/min/1.73 m2 at 7 days and 76.2 mL/min/1.73 m2 at 3 months), and decreased slightly to 72.6 mL/min/1.73 m2 at 1 year. However, in radical nephrectomy patients, mean Chronic Kidney Disease Epidemiology Collaboration glomerular filtration rate decreased immediately to 63.4 mL/min/1.73 m2 at 7 days after surgery, and then increased gradually to 64.6 mL/min/1.73 m2 at 3 months and 65.9 mL/min/1.73 m2 at 1 year. Preoperative mean contralateral normal kidney volume was 225.7 mL in the simple nephrectomy group and 180.1 mL in the radical nephrectomy group (P < 0.001). The contralateral normal kidney volume to total normal kidney volume ratio was 0.74 in the simple nephrectomy group and 0.51 in the radical nephrectomy group (P < 0.001). Conclusions Preoperative volumetric compensation of the contralateral normal kidney is important to maintain postoperative renal function in patients undergoing nephrectomy.
- Published
- 2016
- Full Text
- View/download PDF
126. Percutaneous Kidney Biopsy for a Small Renal Mass: A Critical Appraisal of Results
- Author
-
Hanjong Ahn, Choung-Soo Kim, Hyun Moo Lee, Jun Hyuk Hong, Han-Yong Choi, Byong Chang Jeong, In Gab Jeong, Seong Soo Jeon, Seong Il Seo, Hwang Gyun Jeon, and Cheryn Song
- Subjects
Kidney ,medicine.medical_specialty ,Percutaneous ,medicine.diagnostic_test ,business.industry ,Urology ,030232 urology & nephrology ,Retrospective cohort study ,medicine.disease ,Surgical pathology ,03 medical and health sciences ,0302 clinical medicine ,medicine.anatomical_structure ,Renal cell carcinoma ,030220 oncology & carcinogenesis ,Biopsy ,Carcinoma ,Medicine ,Radiology ,business ,Grading (tumors) - Abstract
Purpose: We report the diagnostic accuracy of renal mass biopsy for a small renal mass (4 cm or less) and identify predictors of successful renal mass biopsy in a contemporary cohort of patients from 2 large tertiary referral centers.Materials and Methods: A total of 442 biopsies of renal tumors 4 cm or less at 2 tertiary centers between 2008 and 2015 were included in study. Biopsy outcomes (malignant, benign or nondiagnostic) and concordance rates between renal mass biopsy and final surgical pathology were determined. Univariate and multivariate logistic regression analyses were performed to identify factors indicative of nondiagnostic biopsy.Results: The initial biopsy was diagnostic in 393 cases (88.9%) and nondiagnostic in 49 (11.1%). Of diagnostic biopsies 76% revealed renal cell carcinoma and 24% were benign. Renal cell carcinoma histological subtyping and grading was possible in 90.2% and 31.3% of cases, respectively. A second biopsy was performed in 11 of the 49 nondiagnostic cases and a diagnosis...
- Published
- 2016
- Full Text
- View/download PDF
127. Tumor size is associated with compensatory hypertrophy in the contralateral kidney after radical nephrectomy in patients with renal cell carcinoma
- Author
-
Seong Ii Seo, Hwang Gyun Jeon, Byong Chang Jeong, Hyun Hwan Sung, Bong Hee Park, Han Yong Choi, Hyun Moo Lee, and Seong Soo Jeon
- Subjects
Male ,Nephrology ,medicine.medical_specialty ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Kidney Volume ,Kidney ,Nephrectomy ,Muscle hypertrophy ,Cohort Studies ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,Risk Factors ,Renal cell carcinoma ,Internal medicine ,Parenchyma ,medicine ,Humans ,Carcinoma, Renal Cell ,Tumor size ,business.industry ,Hypertrophy ,Organ Size ,Middle Aged ,medicine.disease ,Kidney Neoplasms ,Tumor Burden ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Female ,Tomography, X-Ray Computed ,business - Abstract
To assess the association between tumor size and postoperative compensatory hypertrophy of the contralateral kidney estimated with preoperative and postoperative CT in patients with renal cell carcinoma (RCC). We prospectively identified 728 patients who underwent radical nephrectomy for RCC between 2012 and 2014. Contrast-enhanced CT was done within 3 months preoperatively and 1 year postoperatively. A tissue segmentation tool program with CT images was used to estimate kidney volume. We divided patients into three groups according to tumor size (A: ≤4 cm, B: 4–7 cm, C: >7 cm). Preoperative and postoperative volumetric kidney parameters were compared and multivariable linear regression model was used to analyze predictors associated with postoperative compensatory hypertrophy. The preoperative median contralateral kidney volume was significantly larger in group C than in groups A and B (A: 170.3, B: 176.9, C: 186.8 mL, p
- Published
- 2016
- Full Text
- View/download PDF
128. Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance
- Author
-
Seong Soo Jeon, Joung Eun Lim, Hwang Gyun Jeon, Junnam Lee, Hyun Moo Lee, Minyong Kang, Joongwon Choi, Hyun Hwan Sung, Byong Chang Jeong, Seong Il Seo, Jiwoong Yu, and Eun-Hae Cho
- Subjects
Male ,circulating tumor dna ,Oncology ,medicine.medical_specialty ,Somatic cell ,Urology ,030232 urology & nephrology ,lcsh:RC870-923 ,medicine.disease_cause ,prostatic neoplasms ,Germline ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Germline mutation ,Castration Resistance ,Internal medicine ,Republic of Korea ,medicine ,Humans ,Liquid biopsy ,Basic/Translational Research ,Aged ,Retrospective Studies ,Mutation ,Genome ,business.industry ,Hazard ratio ,Liquid Biopsy ,biomarkers ,Prognosis ,lcsh:Diseases of the genitourinary system. Urology ,medicine.disease ,Prostatic Neoplasms, Castration-Resistant ,030220 oncology & carcinogenesis ,Original Article ,castration-resistant ,business - Abstract
Purpose To investigate germline and somatic mutation profiles in Korean patients with prostate cancer using liquid biopsy and solid tissue testing and to evaluate the prognostic value of circulating tumor DNA (ctDNA) in predicting castration resistance in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Materials and Methods Plasma samples from 56 prostate cancer patients were subjected to next-generation sequencing (NGS) to identify germline mutations and ctDNA analysis using liquid biopsy to detect somatic mutations. Additionally, paired solid cancer tissues from 18 patients were subject to NGS to detect somatic mutations. The clinical parameters and ctDNA profiles of patients with mHSPC were analyzed to evaluate the prognostic value of ctDNA mutations with respect to predicting castration resistance using Cox proportional hazards regression analysis. Results Germline mutations occurred in 3.6% of the patients in this cohort, with mutations identified in RAD50 (1.8%) and BRCA1 (1.8%). Somatic mutations detected by liquid biopsy and solid tissue testing were common in TP53 (12.5%), PIK3CA (3.6%), and TMPRSS2-ERG (3.6%). Of the 18 patients with paired tissue testing, two patients had at least one identical somatic mutation in both the liquid biopsy and solid tissue testing. In patients with mHSPC, the presence of ctDNA mutations could independently predict the castration resistance development (hazard ratio, 13.048; 95% confidential interval, 1.109–153.505; p=0.041). Conclusions Korean patients with prostate cancer showed a relatively low germline mutation rate compared to other ethnicities. The ctDNA mutations detected by liquid biopsy can predict the development of castration resistance in patients with mHSPC., Graphical Abstract
- Published
- 2021
- Full Text
- View/download PDF
129. Phase II study of biweekly docetaxel plus androgen-deprivation therapy (ADT) in patients with previously-untreated, metastatic, prostatic adenocarcinoma
- Author
-
Hongsik Kim, Seonggyu Byeon, Seong Soo Jeon, Se Hoon Park, Hyun Moo Lee, Hwang Gyun Jeon, and Hana Kim
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Phases of clinical research ,urologic and male genital diseases ,medicine.disease ,Androgen deprivation therapy ,Prostate cancer ,Docetaxel ,Internal medicine ,medicine ,In patient ,business ,Metastatic Prostatic Adenocarcinoma ,medicine.drug - Abstract
e17580 Background: To evaluate the efficacy and safety of biweekly docetaxel (bD) plus androgen-deprivation therapy (ADT) in metastatic castration-naïve prostate cancer (mCNPC). Methods: This was an open-label, prospective, single-arm phase II trial. 42 patients with mCNPC were treated with docetaxel 40 mg/m2 every two weeks plus ADT. The primary end point was one year castration-resistant prostate cancer (CRPC)-free survival rate and the secondary end points were prostate-specific antigen (PSA) response, time to CRPC and safety. Results: Most patients (87.5%) had Gleason score 8 or more. The median value of PSA at initial treatment was 66.9 ng/ml (range 0.04 to 2339). After bD plus ADT, 39 patients (92.9%) had a PSA response (reduced PSA level 50% or more). The time to CRPC (one-year CRPC free survival 73.6%) and the duration of PSA response (18 months response 80.4%) did not reach the median. The bD plus ADT regimen was well-tolerated. The most common adverse events included neutropenia, nail changes and diarrhea. Conclusions: bD plus ADT treatment demonstrated favorable treatment outcomes with tolerability. Clinical trial information: NCT03061643 .
- Published
- 2020
- Full Text
- View/download PDF
130. Establishment and Validation of Extra-transitional Zone Prostate Specific Antigen Density (ETzD), a Novel Structure-based Parameter for Quantifying the Oncological Hazard of Prostates with Enlarged Stroma
- Author
-
Kyu-Sung Lee, Jung Jun Kim, Seonwoo Kim, Han Yong Choi, Yoon Seok Suh, Hyun Moo Lee, Tae Heon Kim, and Seong Soo Jeon
- Subjects
Male ,0301 basic medicine ,medicine.medical_specialty ,Biopsy ,medicine.medical_treatment ,Enucleation ,Prostatic Hyperplasia ,Urology ,lcsh:Medicine ,Malignancy ,Article ,Cohort Studies ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Prostate ,Biomarkers, Tumor ,medicine ,Humans ,lcsh:Science ,Aged ,Retrospective Studies ,Prostatectomy ,Multidisciplinary ,medicine.diagnostic_test ,business.industry ,lcsh:R ,Prostatic Neoplasms ,Cancer ,Middle Aged ,Prostate-Specific Antigen ,medicine.disease ,Prostate-specific antigen ,030104 developmental biology ,medicine.anatomical_structure ,lcsh:Q ,business ,Algorithms ,030217 neurology & neurosurgery - Abstract
Extra-transitional zone density (ETzD), a novel parameter is proposed to stratify the deviation of prostate specific antigen (PSA) due to structural change according to stromal hyperplasia of prostate. ETzD was conducted on a concept to estimate the PSA density (PSAD) after hypothetical enucleation of the transitional zone of an enlarged prostate by a non-linear regression prediction model with intrinsic linearity, from the retrospective analysis of PSA change observed actual enucleation by laser. The performance to predict the presence and severity of malignancy was validated by two cohorts of 3,440 prostate biopsies and 2,783 radical prostatectomy specimens. The performance of ETzD was compared with conventional parameters. The receiver operative curve of area under curve (AUC) of ETzD to predict the presence of malignacy was 0.862 (95% CI; 0.843~0.881), better than PSA, PSAD or transitional zone PSAD (TzPSAD). The AUC of ETzD to predict an unfavorable cancer among prostate cancer patients was 0.736 (95% CI; 0.705~0.768), which performs better than PSA and comparable to PSAD or TzPSAD. In summary, the performance of ETzD as a universal parameter to quantify the oncological hazard of a prostate was validated and the superiority to conventional parameters was verified.
- Published
- 2019
- Full Text
- View/download PDF
131. Histological characteristics of the largest and secondary tumors in radical prostatectomy specimens and implications for focal therapy
- Author
-
Jiwoong Yu, Byong Chang Jeong, Hwang Gyun Jeon, Young Hyo Choi, Seong Soo Jeon, Hyun Moo Lee, and Seong Il Seo
- Subjects
0301 basic medicine ,Adult ,Male ,medicine.medical_specialty ,Pathology ,Histology ,medicine.medical_treatment ,Urology ,Hemiablation ,Single Center ,Pathology and Forensic Medicine ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Focal therapy ,Republic of Korea ,lcsh:Pathology ,Medicine ,Humans ,Pathological ,Aged ,Aged, 80 and over ,Prostatectomy ,business.industry ,Radical prostatectomy specimen ,Research ,Prostate ,Prostatic Neoplasms ,General Medicine ,Middle Aged ,Prostate-Specific Antigen ,medicine.disease ,Tumor Burden ,Gleason pattern ,030104 developmental biology ,030220 oncology & carcinogenesis ,Secondary tumors ,Hormone therapy ,Histological characteristics ,business ,lcsh:RB1-214 - Abstract
Background Pathological features of prostate cancer in Korean men were analyzed to determine whether identification of tumor volume, Gleason score (GS), focality, and location using radical prostatectomy (RP) specimens can provide useful information for the application of focal therapy (hemiablation). Methods From January 2016 to December 2017, 913 patients who underwent RP at a single center were selected for analysis. Patients with prostate-specific antigen levels > 15 ng/mL or those who had received hormone therapy prior to surgery were excluded. Preoperative data and the number, volume, location, and GS of each tumor were recorded. Results Overall, 762 RP specimens were examined, and 1448 tumors were identified. The majority of the cases were multifocal (60.5%) and bilateral (82%) in nature. Among the 686 secondary tumors, 250 (36.4%) had a GS ≥7 and 122 (17.8%) had a tumor volume ≥ 0.5 mL. Among the 435 bilateral multifocal cases, secondary tumors on the lobes contralateral to the largest tumor were significant by volume (≥0.5 mL) in 91 (20.9%) cases and by grade (GS ≥7) in 179 (41.1%) cases. There were 102 (23.4%) tumors with a small tumor volume (
- Published
- 2019
132. MP68-01 PREOPERATIVE VS POSTOPERATIVE COMPENSATION OF THE CONTRALATERAL NORMAL KIDNEY IN PATIENTS TREATED WITH RADICAL NEPHRECTOMY FOR RENAL CELL CARCINOMA
- Author
-
Seong Soo Jeon, Si Hyun Sung, Hyun Moo Lee, Seong Il Seo, Tae Jin Kim, Seoul Hwang Gyun Jeon, Hyunsoo Ryoo, Hyun Hwan Sung, Min Yong Kang, and Byong Chang Jeong
- Subjects
Kidney ,medicine.medical_specialty ,medicine.anatomical_structure ,Renal cell carcinoma ,business.industry ,Urology ,medicine.medical_treatment ,medicine ,In patient ,medicine.disease ,business ,Nephrectomy - Published
- 2020
- Full Text
- View/download PDF
133. Predictors of postoperative complications after robot-assisted radical cystectomy with extracorporeal urinary diversion
- Author
-
Chung Un, Lee, Minyong, Kang, Tae Jin, Kim, Jun Phil, Na, Hyun Hwan, Sung, Hwang Gyun, Jeon, Seong Il, Seo, Seong Soo, Jeon, Hyun Moo, Lee, and Byong Chang, Jeong
- Subjects
cystectomy ,complications ,robotic surgery ,bladder cancer ,predictor ,Original Research - Abstract
Purpose: Robot-assisted radical cystectomy (RARC) is known to have less postoperative morbidity and complications than open radical cystectomy. However, various complications not yet have been reported after RARC. In this study, we aimed to identify the predictors of complications following RARC. Patients and methods: From August 2008 to November 2017, we retrospectively reviewed 126 patients who underwent RARC with extracorporeal urinary diversion. Overall perioperative complications were examined, and factors that may affect complications were analyzed using a logistic regression model. Complications were classified according to the Clavien-Dindo system. Results: Overall postoperative complications occurred in 78 (61.9%) of 126 patients. Whereas the rate of minor complications was 58.0% (grade I=15.9% (n=20), grade II=42.1% (n=53)), the rate of major complications was very low (grade IIIa=1.6% (n=2), grade IIIb =2.4% (n=3)). No fatal complications more than grade IV were developed. Notably, transfusions (27.0%), urinary tract infection (15.9%), anastomosis site leakage (14.3%), and ileus (10.3%) were the most common complications after RARC. In the multivariate regression model, previous intravesical instillation (odds ration [OR]=3.374), preoperative hemoglobin (OR=0.751), and estimated blood loss (EBL) (OR=3.949) were identified as the predictors of postoperative complications. Conclusion: In sum, our data showed the rates of major complications were comparable after RARC with extracorporeal urinary diversion compared as reported in previous studies and lower major than minor complications following RARC. Moreover, we identified the independent predictors of postoperative complications, such as preoperative hemoglobin, intravesical instillation, and EBL.
- Published
- 2018
134. Cytopathological Study of the Circulating Tumor Cells filtered from the Cancer Patients’ Blood using Hydrogel-based Cell Block Formation
- Author
-
Young Jun Kim, Hyun-Moo Lee, Yoon-Tae Kang, Young-Ho Cho, Tae Hee Lee, and Hee Jin Chang
- Subjects
Male ,0301 basic medicine ,Epithelial-Mesenchymal Transition ,Science ,ICC Staining ,Article ,Cell Line ,03 medical and health sciences ,0302 clinical medicine ,Circulating tumor cell ,Renal cell carcinoma ,Prostate ,Cell Line, Tumor ,Neoplasms ,Biomarkers, Tumor ,medicine ,Humans ,Cell Block ,A549 cell ,Kidney ,Circulating Tumor Cells (CTC) ,Multidisciplinary ,biology ,business.industry ,Renal Cell Carcinoma ,Cancer ,Hydrogels ,Neoplastic Cells, Circulating ,medicine.disease ,Tumor Burden ,Cytopathological Studies ,030104 developmental biology ,medicine.anatomical_structure ,A549 Cells ,Cell culture ,030220 oncology & carcinogenesis ,biology.protein ,Cancer research ,Medicine ,Female ,Antibody ,business - Abstract
Circulating tumor cells have emerged as biomarkers for estimating the tumor burden and metastatic potential of cancer patients. However, to date, most of studies and applications of circulating tumor cells have been conducted and applied to epithelial cancers such as breast, colorectal, and prostate tumor. The only FDA-cleared method, CellSearch, makes use of antibody against epithelial surface protein expressed on CTCs, thus obstructing wide application for various cancers with non-epithelial and semi-epithelial characteristics including renal cell carcinoma. Due to rarity and ambiguity of CTCs, designed experiment including non-biased CTC isolation and subsequent cytopathological study for finding applicable immunomarkers are urgently needed for clinical use of CTCs for less-studied cancers. Here, in order to construct the fundamental step for CTC diagnosis without limitation of its epithelial characteristics, we present the simple and novel method which incorporate both label-free CTC isolation and pathological study using hydrogel-based cell block formation. Six cell lines from lung, ovarian, kidney cancers were used to make cell block and analyzed by conventional immunocytochemical staining method to find the candidate markers for CTC. Especially for renal cancer, the physically isolated CTCs were further immunocytochemically examined with the screened candidate markers by cell block construction, and verified their clinical utility using blood samples from patients with renal cell carcinoma. This comprehensive study demonstrates that the present approach can be used to find the potential markers for any type of cancers regardless of their epithelial characteristics and isolate the specific type of CTCs in label-free manners.
- Published
- 2018
- Full Text
- View/download PDF
135. Combination of multiparametric magnetic resonance imaging and transrectal ultrasound-guided prostate biopsies is not enough for identifying patients eligible for hemiablative focal therapy for prostate cancer
- Author
-
Hyun Moo Lee, Min Yong Kang, Byong Chang Jeong, Seong Soo Jeon, Young Hyo Choi, Jiwoong Yu, Seong Il Seo, Hyun Hwan Sung, and Hwang Gyun Jeon
- Subjects
Ablation Techniques ,Image-Guided Biopsy ,Male ,medicine.medical_specialty ,Prostate biopsy ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Magnetic Resonance Imaging, Interventional ,Multimodal Imaging ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Prostate ,Biopsy ,medicine ,Humans ,Multiparametric Magnetic Resonance Imaging ,Ultrasonography, Interventional ,Retrospective Studies ,Prostatectomy ,medicine.diagnostic_test ,business.industry ,Patient Selection ,Rectum ,Cancer ,Prostatic Neoplasms ,Magnetic resonance imaging ,Middle Aged ,medicine.disease ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Histopathology ,Radiology ,business - Abstract
To evaluate focal therapy (hemiablation) eligibility in men undergoing prostate biopsy and multiparametric magnetic resonance imaging (mpMRI) with reference to histopathology from radical prostatectomy (RP) specimens. Subjects were selected among 810 men who underwent prostate biopsy, mpMRI, and RP from January 2016 to December 2017. Hemiablation eligibility criteria were biopsy-proven unilateral cancer, prostate-specific antigen ≤ 15 ng/ml, and Gleason score (GS) ≤ 3 + 4. Evidence of non-organ-confined disease or Prostate Imaging Reporting and Data System score ≥ 4 on the contralateral lobe on mpMRI was classified as ineligible for hemiablation. Of the 810, data for 185 who met the screening criteria were compared to final pathology findings. Significant cancer at RP was defined as any of the following: (1) GS 6 with tumor volume ≥ 0.5 ml; (2) GS ≥ 3 + 4; or (3) the presence of advanced stage (≥ pT3). Among the 185 candidates for hemiablation, 62 (33.5%) had unilateral cancer on final RP histopathology. Among the 123 bilateral cancers, 50 (27%) were organ confined and had GS ≤ 3 + 4 = 7 and bilateral multifocal tumor in which the index tumor was confined to one lobe and the secondary tumor in the contralateral lobe had tumor volume
- Published
- 2018
136. Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy
- Author
-
Se Hoon Park, Sung Hoo Hong, Cheryn Song, Chang Wook Jeong, Byong Chang Jeong, Jae Young Park, Jinsoo Chung, Cheol Kwak, Han Yong Choi, Seong Il Seo, Hyun Moo Lee, Minyong Kang, Eu Chang Hwang, Seong Soo Jeon, Hyun Hwan Sung, and Hwang Gyun Jeon
- Subjects
Oncology ,Adult ,Male ,medicine.medical_specialty ,Time Factors ,Databases, Factual ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Kaplan-Meier Estimate ,Risk Assessment ,Targeted therapy ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Renal cell carcinoma ,Predictive Value of Tests ,Survivorship curve ,Internal medicine ,Cause of Death ,Carcinoma ,medicine ,Humans ,Molecular Targeted Therapy ,Neoplasm Metastasis ,Survival rate ,Carcinoma, Renal Cell ,Protein Kinase Inhibitors ,Survival analysis ,Aged ,Proportional Hazards Models ,Retrospective Studies ,Proportional hazards model ,business.industry ,Cancer ,Middle Aged ,Protein-Tyrosine Kinases ,medicine.disease ,Prognosis ,Survival Analysis ,Kidney Neoplasms ,030220 oncology & carcinogenesis ,Multivariate Analysis ,Female ,business - Abstract
In this study we evaluated conditional survival probabilities in patients with metastatic renal cell carcinoma who underwent first line tyrosine kinase inhibitor therapy. We also identified predictors of conditional survival with time.We retrospectively reviewed clinical data on 1,659 individuals with metastatic renal cell carcinoma in the Korean Renal Cancer Study Group database, of whom the records of 1,131 were finally analyzed. The primary end point was conditional overall survival. Kaplan-Meier survival analysis was used to calculate conditional overall survival probabilities using the formula, conditional survival (α│β) = S(α + β)/S(β), indicating the likelihood of additional α years survivorship in person who has already survived for β years after initial therapy. S(χ) represents the actual survival rate. Multivariate Cox regression model was used to identify predictors of conditional survival with time.Six, 12, 18, 24 and 36-month conditional overall survival gradually increased in patients at all additional survival times after initial treatment compared to patient baseline survival estimations. While the actual overall survival rate decreased with time, the 36-month conditional overall survival rate was calculated as 7.3% higher in patients who had already survived 36 months compared to baseline estimations at the time of initial tyrosine kinase inhibitor treatment. Furthermore, predictors of conditional overall survival changed with time. Only previous metastasectomy remained a key prognosticator of conditional overall survival until 36 months of survival following initial tyrosine kinase inhibitor treatment.Conditional survival improved with time after initial tyrosine kinase inhibitor treatment in patients with metastatic renal cell carcinoma. Our study offers valuable information for practical survival estimations and relevant prognosticators in patients with metastatic renal cell carcinoma who receive first line tyrosine kinase inhibitor.
- Published
- 2018
137. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience
- Author
-
Minyong Kang, C. Choi, Hwang Gyun Jeon, Hyun Hwan Sung, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, and Byong Chang Jeong
- Subjects
Male ,medicine.medical_specialty ,Urology ,Population ,Antineoplastic Agents ,Kaplan-Meier Estimate ,urologic and male genital diseases ,Single Center ,Nephrectomy ,Metastasis ,03 medical and health sciences ,0302 clinical medicine ,Renal cell carcinoma ,Carcinoma ,Medicine ,Humans ,030212 general & internal medicine ,Molecular Targeted Therapy ,education ,Propensity Score ,Carcinoma, Renal Cell ,Aged ,Retrospective Studies ,education.field_of_study ,business.industry ,Proportional hazards model ,Medical record ,Neoplasms, Second Primary ,Cytoreduction Surgical Procedures ,Middle Aged ,medicine.disease ,Prognosis ,Kidney Neoplasms ,Progression-Free Survival ,Survival Rate ,Oncology ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Propensity score matching ,Female ,business ,Follow-Up Studies - Abstract
To evaluate the prognostic role of cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal-cell carcinoma (mRCC).We analyzed the electronic medical records of 294 patients with synchronous mRCC treated at Samsung Medical Center from January 2005 to December 2015. Primary and secondary end points were overall survival (OS) and cancer-specific survival (CSS), respectively. OS and CSS were estimated by the Kaplan-Meier method and compared between patients with and without CN, particularly by performing 1:1 propensity score matching. Multivariate Cox regression analysis was used to identify independent predictors of survival outcomes.Among the overall population of synchronous mRCC patients, 189 patients (64.3%) underwent CN. Compared to mRCC patients without CN, those who underwent CN have a higher proportion of single metastasis (63.0% vs. 32.4%) and clear-cell histology (87.8% vs. 72.4%). In the matched cohort, the patients who underwent CN had better OS and CSS outcomes compared to those who did not undergo CN (median OS, 23.0 months vs. 11.0 months; P .001; median CSS, 34.0 months vs. 14.0 months; P .001). On multivariable analysis, undergoing CN, body mass index, and Heng risk score were found as significant predictive factors of both OS and CSS. In subgroup analyses stratified by Heng risk criteria, the patients who received CN had better OS and CSS in all risk groups.CN significantly improved survival outcomes in synchronous mRCC patients treated with targeted therapies and independently associated with prolonged survival, regardless of Heng risk criteria.
- Published
- 2018
138. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis
- Author
-
Min Yong Kang, Hyun Hwan Sung, Byung Kwan Park, Seong Soo Jeon, Hwang Gyun Jeon, Hyun Moo Lee, Seong Il Seo, Young Hyo Choi, Byong Chang Jeong, and Chan Kyo Kim
- Subjects
Image-Guided Biopsy ,Male ,medicine.medical_specialty ,Prostate biopsy ,Urology ,030232 urology & nephrology ,urologic and male genital diseases ,Magnetic Resonance Imaging, Interventional ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Prostate ,Biopsy ,medicine ,Humans ,Propensity Score ,Ultrasonography, Interventional ,Aged ,Retrospective Studies ,medicine.diagnostic_test ,business.industry ,Prostatic Neoplasms ,Retrospective cohort study ,Magnetic resonance imaging ,Middle Aged ,Prostate-Specific Antigen ,medicine.disease ,Prostate-specific antigen ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Propensity score matching ,Biopsy, Large-Core Needle ,Neoplasm Grading ,business ,Follow-Up Studies - Abstract
The purpose of the study was to compare cancer detection rates between 12-core transrectal ultrasound-guided prostate biopsy (TRUS-Bx) and multiparametric magnetic resonance imaging (mpMRI)-guided target prostate biopsy (MRI-TBx) according to prostate-specific antigen (PSA) level in biopsy-naive patients.A retrospective study was conducted in 2009 biopsy-naive patients with suspected prostate cancer (PSA ≤20 ng/mL). Patients underwent TRUS-Bx (n = 1786) or MRI-guided target prostate biopsy (MRI-TBx; n = 223) from September 2013 to March 2017 and were stratified according to each of 4 PSA cutoffs. MRI-TBx was performed on lesions with Prostate Imaging Reporting and Data System (PI-RADS) scores of 3 to 5 on mpMRI. Clinically significant prostate cancer (csPCa) was defined as Gleason ≥7. Propensity score matching was performed using the prebiopsy variables, which included age, PSA, prostate volume, and PSA density.Propensity score matching resulted in 222 patients in each group. There were significant differences between the TRUS-Bx and MRI-TBx groups in the overall detection rates of prostate cancer (41.4% vs. 55.4%; P = .003) and csPCa (30.1% vs. 42.8%; P = .005). However, across PSA cutoffs, MRI-TBx detected more prostate cancer than TRUS-Bx at PSA levels of 2.5 to 4 (29.5% vs. 56.6%; P .001). The csPCa detection rates of TRUS-Bx and MRI-TBx did not differ significantly within the PSA cutoffs. There was a significantly higher detection rate of prostate cancer and csPCa in lesions with PI-RADS scores 4 and 5 than in those with a score of 3.Prebiopsy mpMRI and subsequent targeted biopsy had a higher detection rate than TRUS-Bx in patients with prostate cancer and csPCa.
- Published
- 2018
139. PD29-02 IMPACTS OF AGE AND COMORBIDITY ON SURVIVAL VARIES BY RISK GROUP IN PATIENTS WITH PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY: A COMPETING RISK ANALYSIS FROM K-CAP REGISTRY
- Author
-
Kyo Chul Koo, Seung Hwan Lee, Kwang Suk Lee, Byung Ha Chung, In Young Choi, Sung Kyu Hong, Jun Hyuk Hong, Seok-Soo Byun, Koon Ho Rha, Ji Youl Lee, Choung-Soo Kim, and Hyun Moo Lee
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Prostatectomy ,Urology ,medicine.medical_treatment ,Competing risks ,medicine.disease ,Comorbidity ,Prostate cancer ,Risk groups ,Internal medicine ,medicine ,In patient ,business - Published
- 2018
- Full Text
- View/download PDF
140. PD10-01 DOES CURCUMIN PLAY A ROLE IN PROSTATE CANCER SUPPRESSION?: A RANDOMIZED, DOUBLE-BLIND
- Author
-
Byong Chang Jeong, Hyun Hwan Sung, Hwang Gyun Jeon, Seong Il Seo, Deok Hyun Han, Han Yong Choi, Seong Soo Jeon, Young Hyo Choi, and Hyun Moo Lee
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Urology ,medicine.disease ,030227 psychiatry ,Double blind ,03 medical and health sciences ,Prostate cancer ,chemistry.chemical_compound ,0302 clinical medicine ,chemistry ,Internal medicine ,medicine ,Curcumin ,business ,030217 neurology & neurosurgery - Published
- 2018
- Full Text
- View/download PDF
141. Prognostic factors after salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy
- Author
-
Seong Soo Jeon, Hyun Moo Lee, Byong Chang Jeong, Hyun Hwan Sung, Han Yong Choi, Seong Il Seo, Hwang Gyun Jeon, and Wan Song
- Subjects
Male ,Biochemical recurrence ,medicine.medical_specialty ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Median follow-up ,medicine ,Humans ,Treatment Failure ,Stage (cooking) ,Aged ,Neoplasm Staging ,Retrospective Studies ,Prostatectomy ,Salvage Therapy ,Proportional hazards model ,business.industry ,Hazard ratio ,Prostatic Neoplasms ,Middle Aged ,Prostate-Specific Antigen ,Magnetic Resonance Imaging ,Confidence interval ,Surgery ,Radiation therapy ,030220 oncology & carcinogenesis ,Radiotherapy, Intensity-Modulated ,Radiology ,Neoplasm Grading ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies - Abstract
Objectives To evaluate the oncological outcome and to assess prognostic factors of salvage radiotherapy alone in patients with biochemical recurrence after radical prostatectomy. Methods We reviewed our single institution, prospectively maintained database of 2043 patients who underwent radical prostatectomy between September 1995 and December 2011. In this cohort, 149 patients who developed biochemical recurrence after radical prostatectomy and received salvage radiotherapy alone after pelvic magnetic resonance imaging were included. Three-dimensional conformal radiotherapy or intensity-modulated radiotherapy was delivered with a median dose of 70.0 Gy (66.0–78.0 Gy) or 67.2 Gy (64.8–70.0 Gy). Kaplan–Meier and Cox regression analyses were carried out. Results With a median follow up of 82 months (range 20–153 months), 55 patients (36.9%) failed salvage radiotherapy. The 5-year salvage radiotherapy failure-free probability was 53.6%. On multivariate analysis, pre-salvage radiotherapy prostate-specific- antigen ≥1.0 ng/mL (P = 0.003, hazard ratio 3.592, 95% confidence interval 1.522–8.579), pathological stage ≥T3a (P = 0.004, hazard ratio 2.261, 95% confidence interval 1.290–3.833), pathological Gleason score ≥7 (P = 0.018, hazard ratio 5.501, 95% confidence interval 1.577–21.221), prostate-specific antigen doubling time
- Published
- 2015
- Full Text
- View/download PDF
142. The impact of three-dimensional tumor volume on cancer-specific survival for patients with pT1 clear-cell renal cell carcinoma
- Author
-
Hwang Gyun Jeon, Seong Il Seo, Han Yong Choi, Seong Soo Jeon, Hyun Moo Lee, Byong Chang Jeong, and Wan Song
- Subjects
Adult ,Male ,Nephrology ,Oncology ,medicine.medical_specialty ,Adolescent ,Databases, Factual ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Computed tomography ,Kaplan-Meier Estimate ,Nephrectomy ,Cancer specific survival ,Young Adult ,03 medical and health sciences ,Imaging, Three-Dimensional ,0302 clinical medicine ,Renal cell carcinoma ,Internal medicine ,medicine ,Humans ,Child ,Carcinoma, Renal Cell ,Aged ,Neoplasm Staging ,Proportional Hazards Models ,Retrospective Studies ,Aged, 80 and over ,medicine.diagnostic_test ,business.industry ,Proportional hazards model ,Venous phase ,Nephrons ,Middle Aged ,Prognosis ,medicine.disease ,Kidney Neoplasms ,Tumor Burden ,Survival Rate ,Clear cell renal cell carcinoma ,Child, Preschool ,030220 oncology & carcinogenesis ,Multivariate Analysis ,Female ,Tomography, X-Ray Computed ,business ,Organ Sparing Treatments - Abstract
To evaluate the impact of three-dimensional tumor volume on cancer-specific survival for patients with pT1 clear-cell renal cell carcinoma (ccRCC). We reviewed a prospectively maintained database of 917 patients who underwent radical nephrectomy or nephron-sparing surgery for unilateral, pT1 ccRCC, including 654 pT1a and 263 pT1b patients, between April 1997 and December 2010. Three-dimensional tumor volume was measured using specialized volumetric software on cross-sectional computed tomography images of a preoperative venous phase. Kaplan–Meier and Cox regression analyses were carried out. The median age was 54 years with a follow-up of 60.8 months. Median tumor size and volume were 3.2 cm and 17.4 cm3, respectively. Of 917 patients, 54 (5.9 %) had died, including 32 patients with ccRCC (9 patients in pT1a and 23 patients in pT1b). On multivariate analysis, tumor size >3.2 cm and tumor volume >17.4 cm3 were associated with cancer-specific death in pT1 ccRCC patients. When stratified by pT1a/pT1b status and analyzed on median splits, tumor size >2.5 cm was associated with cancer-specific death but not tumor volume >9.5 cm3 in pT1a patients. However, in pT1b patients, tumor volume >62.1 cm3 (P = 0.036, HR 2.91, 95 % CI 1.02–7.77) was highly associated with cancer-specific death but not tumor size >5.0 cm (P = 0.159, HR 1.91, 95 % CI 0.78–4.70). In addition to tumor size, tumor volume is associated with cancer-specific death in pT1 ccRCC patients, particularly in pT1b ccRCC but not in pT1a ccRCC.
- Published
- 2015
- Full Text
- View/download PDF
143. Patient-Derived Xenografts from Non–Small Cell Lung Cancer Brain Metastases Are Valuable Translational Platforms for the Development of Personalized Targeted Therapy
- Author
-
Hyun Moo Lee, Da Eun Jeong, Je-Gun Joung, Woong-Yang Park, Se Jeong Lee, Do-Hyun Nam, Yun Jee Seo, Hye Jin Song, Sang Shin, Yong-Jun Kwon, Ho Jun Seol, Jung-Il Lee, Young Mog Shim, Kyeung Min Joo, Yoon-La Choi, Hye Won Lee, and Hyun-Jung Cho
- Subjects
Male ,Oncology ,Cancer Research ,Pathology ,Lung Neoplasms ,medicine.medical_treatment ,Targeted therapy ,Translational Research, Biomedical ,Mice ,Carcinoma, Non-Small-Cell Lung ,Anaplastic lymphoma kinase ,Anaplastic Lymphoma Kinase ,Molecular Targeted Therapy ,Precision Medicine ,education.field_of_study ,Brain Neoplasms ,Middle Aged ,ErbB Receptors ,Female ,Adult ,medicine.medical_specialty ,Genotype ,Population ,Antineoplastic Agents ,Proto-Oncogene Proteins p21(ras) ,Inhibitory Concentration 50 ,Internal medicine ,medicine ,Carcinoma ,Animals ,Humans ,Lung cancer ,education ,Protein Kinase Inhibitors ,Aged ,Neoplasm Staging ,business.industry ,Gene Expression Profiling ,Receptor Protein-Tyrosine Kinases ,Cancer ,medicine.disease ,Precision medicine ,Xenograft Model Antitumor Assays ,respiratory tract diseases ,Disease Models, Animal ,Mutation ,Drug Screening Assays, Antitumor ,Neoplasm Grading ,business ,Brain metastasis - Abstract
Purpose: The increasing prevalence of distant metastases from non–small cell lung cancer (NSCLC) indicates an urgent need for novel therapeutic modalities. Brain metastasis is particularly common in NSCLC, with severe adverse effects on clinical prognosis. Although the molecular heterogeneity of NSCLC and availability of various targeted agents suggest personalized therapeutic approaches for such brain metastases, further development of appropriate preclinical models is needed to validate the strategies. Experimental Design: We established patient-derived xenografts (PDX) using NSCLC brain metastasis surgical samples and elucidated their possible preclinical and clinical implications for personalized treatment. Results: NSCLC brain metastases (n = 34) showed a significantly higher successful PDX establishment rate than primary specimens (n = 64; 74% vs. 23%). PDXs derived from NSCLC brain metastases recapitulated the pathologic, genetic, and functional properties of corresponding parental tumors. Furthermore, tumor spheres established in vitro from the xenografts under serum-free conditions maintained their in vivo brain metastatic potential. Differential phenotypic and molecular responses to 20 targeted agents could subsequently be screened in vitro using these NSCLC PDXs derived from brain metastases. Although PDX establishment from primary NSCLCs was significantly influenced by histologic subtype, clinical aggressiveness, and genetic alteration status, the brain metastases exhibited consistently adequate in vivo tumor take rate and in vitro tumor sphere formation capacity, regardless of clinical and molecular conditions. Conclusions: Therefore, PDXs from NSCLC brain metastases may better represent the heterogeneous advanced NSCLC population and could be utilized as preclinical models to meet unmet clinical needs such as drug screening for personalized treatments. Clin Cancer Res; 21(5); 1172–82. ©2014 AACR.
- Published
- 2015
- Full Text
- View/download PDF
144. Effects of Complete Bladder Cuff Removal on Oncological Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma.
- Author
-
Hyunsoo Ryoo, Jungyu Kim, Taejin Kim, Minyong Kang, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, and Hyun Hwan Sung
- Subjects
BLADDER cancer ,TRANSITIONAL cell carcinoma ,SURVIVAL analysis (Biometry) ,BLADDER ,OVERALL survival ,KIDNEY pelvis - Abstract
Purpose This study aimed to evaluate the effects of bladder cuff method on oncological outcomes in patients who underwent radical nephroureterectomy (RNU) for upper tract urothelial carcinoma. Materials and Methods The records of 1,095 patients treated with RNU performed at our hospital between 1994 and 2018 were retrospectively reviewed; 856 patients with no bladder tumor history were enrolled in the present study. The management of bladder cuff was divided into two categories: extravesical ligation (EL) or transvesical resection (TR). Survival was analyzed using the Kaplan-Meier method and Cox regression analyses were performed to determine which factors were associated with intravesical recurrence (IVR)-free survival (IVRFS), cancer-specific survival (CSS), and overall survival (OS). Results The mean patient age was 64.8 years and the median follow-up was 37.7 months. Among the 865 patients, 477 (55.7%) underwent the TR and 379 (44.3%) the EL. Significantly higher IVRFS (p=0.001) and OS (p=0.013) were observed in the TR group. In multivariable analysis, IVR, CSS, and OS were independently associated with the EL. Among 379 patients treated with the EL, eight underwent remnant ureterectomy. Based on radical cystectomy-free survival, significant difference was not observed between the two groups. However, significantly higher IVRFS was observed in the TR group when the tumor was located in the renal pelvis. Conclusion Intramural complete excision of the distal ureter during RNU should be the gold standard approach compared with EL for the management of distal ureter in terms of oncological outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
145. Role of PI-RADS Version 2 for Prediction of Upgrading in Biopsy-Proven Prostate Cancer With Gleason Score 6
- Author
-
Hwang Gyun Jeon, Seong Il Seo, Seok Hwan Bang, Hyun Moo Lee, Seong Soo Jeon, Han Yong Choi, Wan Song, Byong Chang Jeong, and Chan Kyo Kim
- Subjects
Adult ,Image-Guided Biopsy ,Male ,medicine.medical_specialty ,Urology ,medicine.medical_treatment ,030232 urology & nephrology ,Gleason Score 6 ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Prostate ,Biopsy ,medicine ,Humans ,Ultrasonography, Interventional ,Aged ,Retrospective Studies ,Aged, 80 and over ,Prostatectomy ,medicine.diagnostic_test ,Receiver operating characteristic ,business.industry ,Prostatic Neoplasms ,Magnetic resonance imaging ,Middle Aged ,Prostate-Specific Antigen ,medicine.disease ,Prognosis ,Magnetic Resonance Imaging ,PI-RADS ,medicine.anatomical_structure ,Logistic Models ,Oncology ,ROC Curve ,030220 oncology & carcinogenesis ,Multivariate Analysis ,Neoplasm Grading ,business - Abstract
Introduction The objective of this study was to investigate the effect of Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) on prediction of postoperative Gleason score (GS) upgrading for patients with biopsy GS 6 prostate cancer. Patients and Methods We retrospectively reviewed 443 patients who underwent magnetic resonance imaging (MRI) and radical prostatectomy for biopsy-proven GS 6 prostate cancer between January 2011 and December 2013. Preoperative clinical variables and pathologic GS were examined, and all MRI findings were assessed with PI-RADSv2. Receiver operating characteristic curves were used to compare predictive accuracies of multivariate logistic regression models with or without PI-RADSv2. Results Of the total 443 patients, 297 (67.0%) experienced GS upgrading postoperatively. PI-RADSv2 scores 1 to 3 and 4 to 5 were identified in 157 (25.4%) and 286 (64.6%) patients, respectively, and the rate of GS upgrading was 54.1% and 74.1%, respectively (P 0.16 ng/mL2, number of positive cores ≥ 2, maximum percentage of cancer per core > 20, and PI-RADSv2 score 4 to 5 were independent predictors influencing GS upgrading (each P Conclusion Use of PI-RADSv2 is an independent predictor of postoperative GS upgrading and increases the predictive accuracy of GS upgrading. PI-RADSv2 might be used as a preoperative imaging tool to determine risk classification and to help counsel patients with regard to treatment decision and prognosis of disease.
- Published
- 2018
146. Prognostic significance of visceral obesity in patients with advanced renal cell carcinoma undergoing nephrectomy
- Author
-
Hyun Moo Lee, Byong Chang Jeong, Seong Soo Jeon, Seong Il Seo, Hwang Gyun Jeon, Hye Won Lee, and Han Yong Choi
- Subjects
medicine.medical_specialty ,Multivariate analysis ,business.industry ,Urology ,medicine.medical_treatment ,Umbilicus (mollusc) ,Subgroup analysis ,medicine.disease ,Gastroenterology ,Obesity ,Nephrectomy ,Surgery ,Renal cell carcinoma ,Internal medicine ,medicine ,Carcinoma ,In patient ,business - Abstract
Objectives To determine the effect of visceral obesity on the prognosis of advanced renal cell carcinoma patients undergoing nephrectomy. Methods We reviewed clinicopathological data of 2187 patients who underwent nephrectomy for renal cell carcinoma (localized [T1–2, N0, M0], n = 1738 [79.5%]; advanced [T3–4, any N and M], n = 449 [20.5%]) at Samsung Medical Center, Seoul, Korea. The visceral fat area and subcutaneous fat area were determined at the level of the umbilicus on computed tomograms obtained before surgery. Patients were categorized as either viscerally obese or non-obese according to visceral fat area and visceral fat area/subcutaneous fat area ratio. Results High visceral fat area (greater than 50 percentiles in each sex) was associated with longer cancer-specific survival (P = 0.01) or overall survival (P = 0.03), whereas visceral fat area/subcutaneous fat area ratio showed no influence on survival outcomes. By multivariate analysis adjusted with clinicopathological variables, low visceral fat area was an independent predictor of cancer-specific death and overall death (cancer-specific survival P = 0.004, hazard ratio = 2.19; overall survival P = 0.003, hazard ratio = 2.22), as well as old age (P = 0.01), radical nephrectomy (P = 0.002), high tumor grade (P = 0.01) and the presence of a sarcomatoid component (P
- Published
- 2015
- Full Text
- View/download PDF
147. Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma
- Author
-
Minyong Kang, Seong Soo Jeon, Hyun Hwan Sung, Seong Il Seo, Jiwoong Yu, Hyun Moo Lee, Byong Chang Jeong, Hwang Gyun Jeon, Han Yong Choi, and Se Hoon Park
- Subjects
Male ,medicine.medical_specialty ,medicine.drug_class ,Urology ,Population ,030232 urology & nephrology ,Aspartate transaminase ,Antineoplastic Agents ,Gastroenterology ,Tyrosine-kinase inhibitor ,03 medical and health sciences ,0302 clinical medicine ,Renal cell carcinoma ,Internal medicine ,Republic of Korea ,Biomarkers, Tumor ,Medicine ,Humans ,Aspartate Aminotransferases ,education ,Carcinoma, Renal Cell ,Protein Kinase Inhibitors ,Aged ,Retrospective Studies ,education.field_of_study ,biology ,business.industry ,Hazard ratio ,Cancer ,Alanine Transaminase ,Middle Aged ,Protein-Tyrosine Kinases ,medicine.disease ,Prognosis ,Survival Analysis ,Kidney Neoplasms ,Treatment Outcome ,Alanine transaminase ,ROC Curve ,030220 oncology & carcinogenesis ,biology.protein ,Female ,Metastasectomy ,business ,Follow-Up Studies - Abstract
OBJECTIVES To examine the prognostic role of the pretreatment aspartate transaminase/alanine transaminase or De Ritis ratio in patients with metastatic renal cell carcinoma receiving first-line systemic tyrosine kinase inhibitor therapy. METHODS We retrospectively searched the medical records of 579 patients with metastatic renal cell carcinoma who visited Samsung Medical Center, Seoul, Korea, from January 2001 through August 2016. After excluding 210 patients, we analyzed 360 patients who received first-line tyrosine kinase inhibitor therapy. Cancer-specific survival and overall survival were defined as the primary and secondary end-points, respectively. A multivariate Cox proportional hazards regression model was used to identify independent prognosticators of survival outcomes. RESULTS The overall population was divided into two groups according to the pretreatment De Ritis ratio as an optimal cut-off value of 1.2, which was determined by a time-dependent receiver operating characteristic curve analysis. Patients with a higher pretreatment De Ritis ratio (≥1.2) had worse cancer-specific survival and overall survival outcomes, compared with those with a lower De Ritis ratio (
- Published
- 2017
148. Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance
- Author
-
Byong Chang Jeong, Hyun Moo Lee, Hwang Gyun Jeon, Jae Ho Yoo, Michelle Ferrari, Seong Soo Jeon, Benjamin I. Chung, Seong Il Seo, Han-Yong Choi, and James D. Brooks
- Subjects
Oncology ,Male ,medicine.medical_treatment ,Biopsy ,030232 urology & nephrology ,lcsh:Medicine ,Logistic regression ,Pathology and Laboratory Medicine ,Prostate cancer ,0302 clinical medicine ,Mathematical and Statistical Techniques ,Prostate ,Medicine and Health Sciences ,Reproductive System Procedures ,lcsh:Science ,Multidisciplinary ,medicine.diagnostic_test ,Prostatectomy ,Prostate Cancer ,Prostate Diseases ,Middle Aged ,Radical Prostatectomy ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Population Surveillance ,Cohort ,Physical Sciences ,Regression Analysis ,Anatomy ,Statistics (Mathematics) ,Research Article ,medicine.medical_specialty ,Clinical Pathology ,Urology ,Surgical and Invasive Medical Procedures ,Research and Analysis Methods ,White People ,03 medical and health sciences ,Exocrine Glands ,Internal medicine ,Republic of Korea ,medicine ,Humans ,Statistical Methods ,Aged ,Surgical Excision ,business.industry ,lcsh:R ,Cancer ,Cancers and Neoplasms ,Biology and Life Sciences ,Prostatic Neoplasms ,Retrospective cohort study ,medicine.disease ,Genitourinary Tract Tumors ,Anatomical Pathology ,Surgical Pathology ,lcsh:Q ,Prostate Gland ,Neoplasm Grading ,business ,Mathematics - Abstract
Purpose To investigate the impact of race on the risk of pathological upgrading and upstaging at radical prostatectomy (RP) in an Asian (Korean) and Western (Caucasian) cohort eligible for active surveillance (AS). Materials and methods We performed a retrospective cohort study of 854 patients eligible for AS who underwent RP in United States (n = 261) and Korea (n = 593) between 2006 and 2015. After adjusting for age, PSA level, and prostate volume, we utilized multivariate logistic regression analysis to assess the effect of race on upgrading or upstaging. Results There were significant differences between Caucasian and Korean patients in terms of age at surgery (60.2 yr. vs. 64.1 yr.), PSA density (0.115 ng/mL/mL vs. 0.165 ng/mL/mL) and mean number of positive cores (3.5 vs. 2.4), but not in preoperative PSA values (5.11 ng/mL vs. 5.05 ng/mL). The rate of upstaging from cT1 or cT2 to pT3 or higher was not significantly different between the two cohorts (8.8% vs. 11.0%, P = 0.341). However, there were higher rates of upgrading to high-grade cancer (Gleason 4+3 or higher) in Korean patients (9.1%) when compared to Caucasian counterparts (2.7%) (P = 0.003). Multivariate logistic regression analysis showed that age (OR 1.07, P < 0.001) and smaller prostate volume (OR 0.97, P < 0.001), but not race, were significantly associated with upstaging or upgrading. Conclusions There were no differences in rates of upgrading or upstaging between Caucasian and Korean men eligible for active surveillance.
- Published
- 2017
149. Predictive Factors for Achieving Superior Pentafecta Outcomes Following Robot-Assisted Partial Nephrectomy in Patients with Localized Renal Cell Carcinoma
- Author
-
Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Seong Il Seo, In-Hyuck Gong, Han Yong Choi, Seong Soo Jeon, Hyun Moo Lee, Hwi Jun Park, and Byong Chang Jeong
- Subjects
Adult ,Male ,medicine.medical_specialty ,Urology ,medicine.medical_treatment ,Operative Time ,030232 urology & nephrology ,Blood Loss, Surgical ,Renal function ,Comorbidity ,urologic and male genital diseases ,Nephrectomy ,03 medical and health sciences ,0302 clinical medicine ,Postoperative Complications ,Robotic Surgical Procedures ,Renal cell carcinoma ,Medicine ,Humans ,In patient ,Warm Ischemia ,Renal Insufficiency, Chronic ,Carcinoma, Renal Cell ,Neoplasm Staging ,Retrospective Studies ,Surgeons ,business.industry ,Margins of Excision ,Retrospective cohort study ,Perioperative ,Middle Aged ,medicine.disease ,Kidney Neoplasms ,Surgery ,Tumor Burden ,Logistic Models ,Treatment Outcome ,030220 oncology & carcinogenesis ,Hypertension ,Multivariate Analysis ,Operative time ,Neoplasm staging ,Female ,business ,Glomerular Filtration Rate - Abstract
To examine the perioperative outcomes following robot-assisted partial nephrectomy (RAPN) in patients with localized renal cell carcinoma (RCC) and to identify the predictors of Pentafecta achievement following RAPN.We retrospectively analyzed the data from 362 patients with RCC who underwent RAPN from 2008 to 2016. The criteria for Pentafecta achievement were defined as the Trifecta [warm ischemic time (WIT) ≤25 minutes, negative surgical margin, and no significant perioperative complications]; with the addition of renal function preservation, including over 90% preservation of the estimated glomerular filtration rate (e-GFR); and no stage upgrade of chronic kidney disease at 1 year after surgery. Multivariate logistic regression analysis was performed to determine the predictors of the Pentafecta outcomes.Among 362 patients, 82.3% (n = 298) had clinical T1a tumors. The median tumor size was 2.9 cm [interquartile range (IQR) = 2.1-3.6] and median nephrometry score was 7 (IQR = 6-8). The median operative time was 220 minutes (IQR = 185-270) and median estimated blood loss was 150 mL (IQR = 100-200). The median WIT was 20 minutes (IQR = 16-26). The overall rate of postoperative complications was 18.8% (n = 68). The rates of Trifecta and Pentafecta achievement were 66.6% (n = 241/362) and 33.9% (n = 121/303), respectively. Notably, the preoperative e-GFR, hypertension, tumor size, L-component of the R.E.N.A.L score, and surgeon's experience were identified as the significant predictors of Pentafecta achievement. Additionally, patients with T1a tumors showed higher rates of Pentafecta achievement (45.7% vs 25.9%) compared with those of patients with T1b tumors. However, there was no significant difference in the Pentafecta accomplishment rates between the transperitoneal and retroperitoneal approaches.In summary, our data highlighted that tumor size and nephrometry score, which are tumor-related factors, as well as the surgeon's experience, a surgeon-related factor, appear to be the critical predictive factors for Pentafecta achievement following RAPN.
- Published
- 2017
150. A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer
- Author
-
Byong Chang Jeong, Hyun Moo Lee, Ji Yun Lee, Hae Su Kim, Hyun Hwan Sung, Seong Il Seo, Han Yong Choi, Ho Yeong Lim, Seong Soo Jeon, Hwang Gyun Jeon, Se Hoon Park, and Su Jin Lee
- Subjects
Male ,Oncology ,medicine.medical_specialty ,Urology ,medicine.medical_treatment ,Antineoplastic Agents ,Docetaxel ,urologic and male genital diseases ,Biweekly ,Drug Administration Schedule ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Asian People ,Internal medicine ,medicine ,Clinical endpoint ,Humans ,030212 general & internal medicine ,Neoplasm Metastasis ,Aged ,Retrospective Studies ,Aged, 80 and over ,Chemotherapy ,business.industry ,Retrospective cohort study ,General Medicine ,Middle Aged ,medicine.disease ,Discontinuation ,Prostatic Neoplasms, Castration-Resistant ,Regimen ,Treatment Outcome ,Reproductive Medicine ,030220 oncology & carcinogenesis ,Prednisolone ,Feasibility Studies ,Taxoids ,Castrate-resistant prostate cancer ,business ,Research Article ,medicine.drug - Abstract
Background The aim of this retrospective study was to evaluate the clinical outcomes of reduced dose, biweekly docetaxel chemotherapy for Korean patients with castrate-resistant prostate cancer (CRPC). Methods We retrospectively reviewed the medical records of 48 patients with metastatic CRPC who were treated with a biweekly regimen (intravenous docetaxel 40 mg/m2 on day 1 plus prednisolone 5 mg twice daily) between 2012 and 2015 at Samsung Medical Center (Seoul, Korea). Prior to the adoption of a biweekly regimen in Oct 2013, our institutional standard chemotherapy was docetaxel 75 mg/m2 every 3 weeks for patients with CRPC (n = 24). After Oct 2013, all chemotherapy-naïve patients with CRPC received a 40 mg/m2 biweekly regimen (n = 24). The primary end point was a PSA response, defined as a greater than 50% decline in PSA level from baseline. Results The baseline characteristics of the patients in the two treatment groups were similar. The most common cause of treatment discontinuation was disease progression, which was exhibited by 17 patients (71%) in the 3-weekly group and 20 (75%) in the biweekly group. PSA responses were observed in 12 (50%) and 11 (46%) patients in the 3-weekly and biweekly groups, respectively (p = 0.683). Time to treatment failure (TTTF, 4.5 vs 3.9 months) and time-to-progression (TTP, 5.0 vs 4.2 months) were not significantly different between the 3-weekly and biweekly groups. Conclusions Within the limitations of a retrospective study, the biweekly reduced dose docetaxel regimen was active and well-tolerated in Korean patients with metastatic CRPC.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.